,sentence_text,e1_text,e2_text,relation_type,normalized_sentence
0,"We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. ",DZNep,ABT-737,effect,also found Bcl 2 overexpressed DZNep insensitive cells cotreatment DRUG_N DRUG_N Bcl 2 family inhibitor synergistically inhibited growth induced apoptosis DZNep insensitive MM cells.
1,"In addition, DZNep insensitivity might be associated with overexpression of Bcl-2, and the combination of ABT-737 and DZNep could synergistically induced apoptosis. ",ABT-737,DZNep,effect,addition DZNep insensitivity might associated overexpression Bcl 2 combination DRUG_N DRUG_N could synergistically induced apoptosis.
2,"Ephedrine enhances the antinociceptive effect of dexmedetomidine in mice.
",Ephedrine,dexmedetomidine,effect,DRUG enhances antinociceptive effect DRUG mice.
3,"In the hot plate test in mice, co-administration of 15     g/kg dexmedetomidine with 10   mg/kg ephedrine intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by dexmedetomidine. ",dexmedetomidine,ephedrine,effect,hot plate test mice co administration 15 g/kg DRUG 10 mg/kg DRUG intraperitoneally enhanced also prolonged duration antinociception induced dexmedetomidine.
4,"At the same time, the locomotor inhibitory effect of dexmedetomidine was counteracted by ephedrine. ",dexmedetomidine,ephedrine,effect,time locomotor inhibitory effect DRUG counteracted DRUG .
5,"We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.",dexmedetomidine,ephedrine,effect,concluded combined administration DRUG DRUG may beneficial effects treatment pain without causing sedation limits use dexmedetomidine analgesic humans.
6,"CYP3A4 Inhibitors: Ketoconazole, an inhibitor of the drug metabolizing enzyme CYP3A4, significantly increased plasma concentrations of tolterodine when coadministered to subjects who were poor metabolizers (see CLINICAL PHARMACOLOGY, Variability in Metabolism and Drug-Drug Interactions). ",Ketoconazole,tolterodine,mechanism,CYP3A4 Inhibitors: DRUG inhibitor drug metabolizing enzyme CYP3A4 significantly increased plasma concentrations DRUG coadministered subjects poor metabolizers (see CLINICAL PHARMACOLOGY Variability Metabolism Drug Drug Interactions).
7,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",ketoconazole,DETROL LA,advise,patients receiving DRUG potent CYP3A4 inhibitors azole antifungals (eg itraconazole miconazole) macrolide antibiotics (eg erythromycin clarithromycin) cyclosporine vinblastine recommended dose BRAND 2 mg daily.
8,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",azole antifungals,DETROL LA,advise,patients receiving ketoconazole potent CYP3A4 inhibitors GROUP (eg itraconazole miconazole) macrolide antibiotics (eg erythromycin clarithromycin) cyclosporine vinblastine recommended dose BRAND 2 mg daily.
9,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",itraconazole,DETROL LA,advise,patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals (eg DRUG miconazole) macrolide antibiotics (eg erythromycin clarithromycin) cyclosporine vinblastine recommended dose BRAND 2 mg daily.
10,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",miconazole,DETROL LA,advise,patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals (eg itraconazole DRUG ) macrolide antibiotics (eg erythromycin clarithromycin) cyclosporine vinblastine recommended dose BRAND 2 mg daily.
11,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",macrolide antibiotics,DETROL LA,advise,patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals (eg itraconazole miconazole) GROUP (eg erythromycin clarithromycin) cyclosporine vinblastine recommended dose BRAND 2 mg daily.
12,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",erythromycin,DETROL LA,advise,patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals (eg itraconazole miconazole) macrolide antibiotics (eg DRUG clarithromycin) cyclosporine vinblastine recommended dose BRAND 2 mg daily.
13,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",clarithromycin,DETROL LA,advise,patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals (eg itraconazole miconazole) macrolide antibiotics (eg erythromycin DRUG ) cyclosporine vinblastine recommended dose BRAND 2 mg daily.
14,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",cyclosporine,DETROL LA,advise,patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals (eg itraconazole miconazole) macrolide antibiotics (eg erythromycin clarithromycin) DRUG vinblastine recommended dose BRAND 2 mg daily.
15,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",vinblastine,DETROL LA,advise,patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals (eg itraconazole miconazole) macrolide antibiotics (eg erythromycin clarithromycin) cyclosporine DRUG recommended dose BRAND 2 mg daily.
16,"Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol. ",paliperidone,centrally acting drugs,advise,Given primary CNS effects DRUG INVEGA used caution combination GROUP alcohol.
17,"Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol. ",paliperidone,alcohol,advise,Given primary CNS effects DRUG INVEGA used caution combination centrally acting drugs DRUG .
18,"Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol. ",INVEGA,centrally acting drugs,advise,Given primary CNS effects paliperidone BRAND used caution combination GROUP alcohol.
19,"Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol. ",INVEGA,alcohol,advise,Given primary CNS effects paliperidone BRAND used caution combination centrally acting drugs DRUG .
20,Paliperidone may antagonize the effect of levodopa and other dopamine agonists. ,Paliperidone,levodopa,effect,DRUG may antagonize effect DRUG dopamine agonists.
21,Paliperidone may antagonize the effect of levodopa and other dopamine agonists. ,Paliperidone,dopamine agonists,effect,DRUG may antagonize effect levodopa GROUP .
22,"The concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects. ",oxybutynin,anticholinergic drugs,effect,concomitant use DRUG GROUP agents produce dry mouth constipation somnolence (drowsiness) and/or anticholinergic like effects may increase frequency and/or severity effects.
23,"Mean oxybutynin chloride plasma concentrations were approximately 2 fold higher when DITROPAN XL was administered with ketoconazole, a potent CYP3A4 inhibitor. ",DITROPAN XL,ketoconazole,mechanism,Mean oxybutynin chloride plasma concentrations approximately 2 fold higher BRAND administered DRUG potent CYP3A4 inhibitor.
24,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",antimycotic agents,oxybutynin,mechanism,inhibitors cytochrome P450 3A4 enzyme system GROUP (e.g. itraconazole miconazole) macrolide antibiotics (e.g. erythromycin clarithromycin) may alter DRUG mean pharmacokinetic parameters (i.e. Cmax AUC).
25,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",itraconazole,oxybutynin,mechanism,inhibitors cytochrome P450 3A4 enzyme system antimycotic agents (e.g. DRUG miconazole) macrolide antibiotics (e.g. erythromycin clarithromycin) may alter DRUG mean pharmacokinetic parameters (i.e. Cmax AUC).
26,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",miconazole,oxybutynin,mechanism,inhibitors cytochrome P450 3A4 enzyme system antimycotic agents (e.g. itraconazole DRUG ) macrolide antibiotics (e.g. erythromycin clarithromycin) may alter DRUG mean pharmacokinetic parameters (i.e. Cmax AUC).
27,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",macrolide antibiotics,oxybutynin,mechanism,inhibitors cytochrome P450 3A4 enzyme system antimycotic agents (e.g. itraconazole miconazole) GROUP (e.g. erythromycin clarithromycin) may alter DRUG mean pharmacokinetic parameters (i.e. Cmax AUC).
28,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",erythromycin,oxybutynin,mechanism,inhibitors cytochrome P450 3A4 enzyme system antimycotic agents (e.g. itraconazole miconazole) macrolide antibiotics (e.g. DRUG clarithromycin) may alter DRUG mean pharmacokinetic parameters (i.e. Cmax AUC).
29,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",clarithromycin,oxybutynin,mechanism,inhibitors cytochrome P450 3A4 enzyme system antimycotic agents (e.g. itraconazole miconazole) macrolide antibiotics (e.g. erythromycin DRUG ) may alter DRUG mean pharmacokinetic parameters (i.e. Cmax AUC).
30,"Mitotane has been reported to accelerate the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for warfarin. ",Mitotane,warfarin,mechanism,DRUG reported accelerate metabolism DRUG mechanism hepatic microsomal enzyme induction leading increase dosage requirements warfarin.
31,"Therefore, physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering Mitotane to patients on coumarin-type anticoagulants. ",Mitotane,coumarin-type anticoagulants,advise,Therefore physicians closely monitor patients change anticoagulant dosage requirements administering DRUG patients GROUP .
32,Concomitant administration of vancomycin and anesthetic agents has been associated with erythema and histamine-like flushing and anaphylactoid reactions. ,vancomycin,anesthetic agents,effect,Concomitant administration DRUG GROUP associated erythema histamine like flushing anaphylactoid reactions.
33,"(ii) acetyl-l-carnitine elicits a significant protective effect on DEB induced toxicity, which was potentiated by  alpha-lipoic acid.",acetyl-l-carnitine,alpha-lipoic acid,effect,(ii) DRUG elicits significant protective effect DEB induced toxicity potentiated DRUG .
34,"However, the co   administration of SPIRIVA with other anticholinergic   containing drugs (e.g., ipratropium) has not been studied and is therefore not recommended.",SPIRIVA,anticholinergic,advise,However co administration BRAND GROUP containing drugs (e.g. ipratropium) studied therefore recommended.
35,"However, the co   administration of SPIRIVA with other anticholinergic   containing drugs (e.g., ipratropium) has not been studied and is therefore not recommended.",SPIRIVA,ipratropium,advise,However co administration BRAND anticholinergic containing drugs (e.g. DRUG ) studied therefore recommended.
36,Prothrombin time or other suitable anticoagulation test should be monitored if tigecycline is administered with warfarin.   ,tigecycline,warfarin,advise,Prothrombin time suitable anticoagulation test monitored DRUG administered DRUG .
37,Concurrent use of antibacterial drugs with oral contraceptives may render oral contraceptives less effective.  ,antibacterial drugs,contraceptives,effect,Concurrent use GROUP oral GROUP may render oral contraceptives less effective.
38,"The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.
",dasatinib,paclitaxel,effect,role p27(Kip1) DRUG enhanced DRUG cytotoxicity human ovarian cancer cells.
39,HEY cells treated with dasatinib plus paclitaxel formed fewer colonies than did cells treated with either agent alone. ,dasatinib,paclitaxel,effect,HEY cells treated DRUG plus DRUG formed fewer colonies cells treated either agent alone.
40,"Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",dasatinib,paclitaxel,effect,Treatment HEY xenograft bearing mice DRUG plus DRUG inhibited tumor growth treatment either agent alone (average tumor volume per mouse dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3 difference = 0.53 cm3 95% confidence interval [CI] = 0.44 0.62 cm3 P = .014);
41,Studies with forced expression and siRNA knockdown of Bcl-2 and Cdk1 suggest that dasatinib-mediated induction of p27(Kip1) enhanced paclitaxel-induced apoptosis by negatively regulating Bcl-2 and Cdk1 expression. ,dasatinib,paclitaxel,effect,Studies forced expression siRNA knockdown Bcl 2 Cdk1 suggest DRUG mediated induction p27(Kip1) enhanced DRUG induced apoptosis negatively regulating Bcl 2 Cdk1 expression.
42,Inhibition of Src family and Abl kinases with either siRNAs or dasatinib enhances paclitaxel sensitivity of ovarian cancer cells through p27(Kip1)-mediated suppression of Bcl-2 and Cdk1 expression.,dasatinib,paclitaxel,effect,Inhibition Src family Abl kinases either siRNAs DRUG enhances DRUG sensitivity ovarian cancer cells p27(Kip1) mediated suppression Bcl 2 Cdk1 expression.
43,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",Triprolidine,central nervous system depressants,effect,DRUG may enhance sedative effects GROUP including alcohol barbiturates hypnotics narcotic analgesics sedatives tranquillisers.
44,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",Triprolidine,alcohol,effect,DRUG may enhance sedative effects central nervous system depressants including DRUG barbiturates hypnotics narcotic analgesics sedatives tranquillisers.
45,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",Triprolidine,barbiturates,effect,DRUG may enhance sedative effects central nervous system depressants including alcohol GROUP hypnotics narcotic analgesics sedatives tranquillisers.
46,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",Triprolidine,hypnotics,effect,DRUG may enhance sedative effects central nervous system depressants including alcohol barbiturates GROUP narcotic analgesics sedatives tranquillisers.
47,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",Triprolidine,narcotic analgesics,effect,DRUG may enhance sedative effects central nervous system depressants including alcohol barbiturates hypnotics GROUP sedatives tranquillisers.
48,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",Triprolidine,sedatives,effect,DRUG may enhance sedative effects central nervous system depressants including alcohol barbiturates hypnotics narcotic analgesics GROUP tranquillisers.
49,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",Triprolidine,tranquillisers,effect,DRUG may enhance sedative effects central nervous system depressants including alcohol barbiturates hypnotics narcotic analgesics sedatives GROUP .
50,"The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine. ",anticholinergic drugs,triprolidine,effect,effects GROUP atropine tricyclic antidepressants may enhanced concomitant administration DRUG .
51,"The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine. ",atropine,triprolidine,effect,effects anticholinergic drugs DRUG tricyclic antidepressants may enhanced concomitant administration DRUG .
52,"The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine. ",tricyclic antidepressants,triprolidine,effect,effects anticholinergic drugs atropine GROUP may enhanced concomitant administration DRUG .
53,"Interaction of celecoxib with different anti-cancer drugs is antagonistic in breast but not in other cancer cells.
",celecoxib,anti-cancer drugs,effect,Interaction DRUG different GROUP antagonistic breast cancer cells.
54,We found antagonism between celecoxib and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between celecoxib and doxorubicin in all cell lines except for two combinations in HCT116 cells. ,celecoxib,doxorubicin,effect,found antagonism celecoxib four drugs breast cancer cells MCF7 following incubation schedules DRUG DRUG cell lines except two combinations HCT116 cells.
55,Caution should be exercised when Methergine    (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.,Methergine,vasoconstrictors,advise,Caution exercised BRAND (methylergonovine maleate) used concurrently GROUP ergot alkaloids.
56,Caution should be exercised when Methergine    (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.,Methergine,ergot alkaloids,advise,Caution exercised BRAND (methylergonovine maleate) used concurrently vasoconstrictors GROUP .
57,Caution should be exercised when Methergine    (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.,methylergonovine maleate,vasoconstrictors,advise,Caution exercised Methergine ( DRUG ) used concurrently GROUP ergot alkaloids.
58,"The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see",AGGRASTAT,heparin,effect,use BRAND combination DRUG aspirin associated increase bleeding compared heparin aspirin alone (see
59,"The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see",AGGRASTAT,aspirin,effect,use BRAND combination heparin BRAND associated increase bleeding compared heparin aspirin alone (see
60,"however, in patients with Paget's Disease prior diphosphonate use appears to reduce the anti-resorptive response to Calcitonin (salmon) nasal spray.",diphosphonate,Calcitonin (salmon),effect,however patients Paget's Disease prior GROUP use appears reduce anti resorptive response DRUG nasal spray.
61,patients receiving lithium and Neulasta should have more frequent monitoring of neutrophil counts.,lithium,Neulasta,advise,patients receiving DRUG BRAND frequent monitoring neutrophil counts.
62,Sirolimus AUC was increased by 21% with no effect on Cmax in the presence of steady-state MYCAMINE compared with sirolimus alone. ,Sirolimus,MYCAMINE,mechanism,DRUG AUC increased 21% effect Cmax presence steady state BRAND compared sirolimus alone.
63,"Nifedipine AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state MYCAMINE compared with nifedipine alone. ",Nifedipine,MYCAMINE,mechanism,DRUG AUC Cmax increased 18% 42% respectively presence steady state BRAND compared nifedipine alone.
64,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,sirolimus,MYCAMINE,advise,Patients receiving DRUG nifedipine combination BRAND monitored sirolimus nifedipine toxicity sirolimus nifedipine dosage reduced necessary.
65,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,nifedipine,MYCAMINE,advise,Patients receiving sirolimus DRUG combination BRAND monitored sirolimus nifedipine toxicity sirolimus nifedipine dosage reduced necessary.
66,"Dosages of concomitantly administered opioids should be reduced by approximately half, because levomepromazine amplifies the therapeutic actions and side-effects of opioids. ",opioids,levomepromazine,effect,Dosages concomitantly administered GROUP reduced approximately half DRUG amplifies therapeutic actions side effects opioids.
67,"Dosages of concomitantly administered opioids should be reduced by approximately half, because levomepromazine amplifies the therapeutic actions and side-effects of opioids. ",levomepromazine,opioids,effect,Dosages concomitantly administered opioids reduced approximately half DRUG amplifies therapeutic actions side effects GROUP .
68,Additive sedative effects and confusional states may emerge if levomepromazine is given with benzodiazepines or barbiturates. ,levomepromazine,benzodiazepines,effect,Additive sedative effects confusional states may emerge DRUG given GROUP barbiturates.
69,Additive sedative effects and confusional states may emerge if levomepromazine is given with benzodiazepines or barbiturates. ,levomepromazine,barbiturates,effect,Additive sedative effects confusional states may emerge DRUG given benzodiazepines GROUP .
70,"Exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. ",levomepromazine,anticholinergic drugs,advise,Exert particular caution combining DRUG GROUP (tricyclic antidepressants antiparkinsonian agents): Particularly elderly may develop delirium high fever severe obstipation even ileus glaucoma.
71,"Exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. ",levomepromazine,tricyclic antidepressants,advise,Exert particular caution combining DRUG anticholinergic drugs ( GROUP antiparkinsonian agents): Particularly elderly may develop delirium high fever severe obstipation even ileus glaucoma.
72,"Exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. ",levomepromazine,antiparkinsonian-agents,advise,Exert particular caution combining DRUG anticholinergic drugs (tricyclic antidepressants GROUP ): Particularly elderly may develop delirium high fever severe obstipation even ileus glaucoma.
73,Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine. ,Caffeine,levomepromazine,effect,DRUG and/or stimulantes ephedrine/amphetamine type may counteract specific actions DRUG .
74,Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine. ,ephedrine,levomepromazine,effect,Caffeine and/or stimulantes DRUG /amphetamine type may counteract specific actions DRUG .
75,Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine. ,amphetamine,levomepromazine,effect,Caffeine and/or stimulantes ephedrine/ DRUG type may counteract specific actions DRUG .
76,Prior administration of succinylcholine can potentiate the neuromuscular blocking effects of nondepolarizing agents. ,succinylcholine,nondepolarizing agents,effect,Prior administration DRUG potentiate neuromuscular blocking effects GROUP .
77,Evidence of spontaneous recovery from succinylcholine should be observed before the administration of MIVACRON. ,succinylcholine,MIVACRON,advise,Evidence spontaneous recovery DRUG observed administration BRAND .
78,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,antibiotics,int,drugs may enhance neuromuscular blocking action DRUG MIVACRON include certain GROUP (e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
79,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,aminoglycosides,int,drugs may enhance neuromuscular blocking action DRUG MIVACRON include certain antibiotics (e.g. GROUP tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
80,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,tetracyclines,int,drugs may enhance neuromuscular blocking action DRUG MIVACRON include certain antibiotics (e.g. aminoglycosides GROUP bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
81,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,bacitracin,int,drugs may enhance neuromuscular blocking action DRUG MIVACRON include certain antibiotics (e.g. aminoglycosides tetracyclines DRUG polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
82,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,polymyxins,int,drugs may enhance neuromuscular blocking action DRUG MIVACRON include certain antibiotics (e.g. aminoglycosides tetracyclines bacitracin GROUP lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
83,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,lincomycin,int,drugs may enhance neuromuscular blocking action DRUG MIVACRON include certain antibiotics (e.g. aminoglycosides tetracyclines bacitracin polymyxins DRUG clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
84,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,clindamycin,int,drugs may enhance neuromuscular blocking action DRUG MIVACRON include certain antibiotics (e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin DRUG colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
85,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,colistin,int,drugs may enhance neuromuscular blocking action DRUG MIVACRON include certain antibiotics (e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin DRUG sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
86,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,sodium colistimethate,int,drugs may enhance neuromuscular blocking action DRUG MIVACRON include certain antibiotics (e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin DRUG ) magnesium salts lithium local anesthetics procainamide quinidine.
87,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,magnesium,int,drugs may enhance neuromuscular blocking action DRUG MIVACRON include certain antibiotics (e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) GROUP salts lithium local anesthetics procainamide quinidine.
88,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,lithium,int,drugs may enhance neuromuscular blocking action DRUG MIVACRON include certain antibiotics (e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts DRUG local anesthetics procainamide quinidine.
89,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,anesthetics,int,drugs may enhance neuromuscular blocking action DRUG MIVACRON include certain antibiotics (e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local GROUP procainamide quinidine.
90,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,procainamide,int,drugs may enhance neuromuscular blocking action DRUG MIVACRON include certain antibiotics (e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics DRUG quinidine.
91,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,quinidine,int,drugs may enhance neuromuscular blocking action DRUG MIVACRON include certain antibiotics (e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide DRUG .
92,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,antibiotics,int,drugs may enhance neuromuscular blocking action nondepolarizing agents BRAND include certain GROUP (e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
93,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,aminoglycosides,int,drugs may enhance neuromuscular blocking action nondepolarizing agents BRAND include certain antibiotics (e.g. GROUP tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
94,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,tetracyclines,int,drugs may enhance neuromuscular blocking action nondepolarizing agents BRAND include certain antibiotics (e.g. aminoglycosides GROUP bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
95,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,bacitracin,int,drugs may enhance neuromuscular blocking action nondepolarizing agents BRAND include certain antibiotics (e.g. aminoglycosides tetracyclines DRUG polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
96,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,polymyxins,int,drugs may enhance neuromuscular blocking action nondepolarizing agents BRAND include certain antibiotics (e.g. aminoglycosides tetracyclines bacitracin GROUP lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
97,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,lincomycin,int,drugs may enhance neuromuscular blocking action nondepolarizing agents BRAND include certain antibiotics (e.g. aminoglycosides tetracyclines bacitracin polymyxins DRUG clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
98,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,clindamycin,int,drugs may enhance neuromuscular blocking action nondepolarizing agents BRAND include certain antibiotics (e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin DRUG colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
99,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,colistin,int,drugs may enhance neuromuscular blocking action nondepolarizing agents BRAND include certain antibiotics (e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin DRUG sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
100,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,sodium colistimethate,int,drugs may enhance neuromuscular blocking action nondepolarizing agents BRAND include certain antibiotics (e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin DRUG ) magnesium salts lithium local anesthetics procainamide quinidine.
101,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,magnesium,int,drugs may enhance neuromuscular blocking action nondepolarizing agents BRAND include certain antibiotics (e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) GROUP salts lithium local anesthetics procainamide quinidine.
102,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,lithium,int,drugs may enhance neuromuscular blocking action nondepolarizing agents BRAND include certain antibiotics (e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts DRUG local anesthetics procainamide quinidine.
103,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,anesthetics,int,drugs may enhance neuromuscular blocking action nondepolarizing agents BRAND include certain antibiotics (e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local GROUP procainamide quinidine.
104,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,procainamide,int,drugs may enhance neuromuscular blocking action nondepolarizing agents BRAND include certain antibiotics (e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics DRUG quinidine.
105,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,quinidine,int,drugs may enhance neuromuscular blocking action nondepolarizing agents BRAND include certain antibiotics (e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide DRUG .
106,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",MIVACRON,contraceptives,effect,neuromuscular blocking effect BRAND may enhanced drugs reduce plasma cholinesterase activity (e.g. chronically administered oral GROUP glucocorticoids certain monoamine oxidase inhibitors) drugs irreversibly inhibit plasma cholinesterase . Resistance neuromuscular blocking action nondepolarizing neuromuscular blocking agents demonstrated patients chronically administered phenytoin carbamazepine.
107,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",MIVACRON,glucocorticoids,effect,neuromuscular blocking effect BRAND may enhanced drugs reduce plasma cholinesterase activity (e.g. chronically administered oral contraceptives GROUP certain monoamine oxidase inhibitors) drugs irreversibly inhibit plasma cholinesterase . Resistance neuromuscular blocking action nondepolarizing neuromuscular blocking agents demonstrated patients chronically administered phenytoin carbamazepine.
108,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",MIVACRON,monoamine oxidase inhibitors,effect,neuromuscular blocking effect BRAND may enhanced drugs reduce plasma cholinesterase activity (e.g. chronically administered oral contraceptives glucocorticoids certain GROUP ) drugs irreversibly inhibit plasma cholinesterase . Resistance neuromuscular blocking action nondepolarizing neuromuscular blocking agents demonstrated patients chronically administered phenytoin carbamazepine.
109,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",neuromuscular blocking agents,phenytoin,effect,neuromuscular blocking effect MIVACRON may enhanced drugs reduce plasma cholinesterase activity (e.g. chronically administered oral contraceptives glucocorticoids certain monoamine oxidase inhibitors) drugs irreversibly inhibit plasma cholinesterase . Resistance neuromuscular blocking action nondepolarizing GROUP demonstrated patients chronically administered DRUG carbamazepine.
110,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",neuromuscular blocking agents,carbamazepine,effect,neuromuscular blocking effect MIVACRON may enhanced drugs reduce plasma cholinesterase activity (e.g. chronically administered oral contraceptives glucocorticoids certain monoamine oxidase inhibitors) drugs irreversibly inhibit plasma cholinesterase . Resistance neuromuscular blocking action nondepolarizing GROUP demonstrated patients chronically administered phenytoin DRUG .
111,"While the effects of chronic phenytoin or carbamazepine therapy on the action of MIVACRON are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher. ",phenytoin,MIVACRON,effect,effects chronic DRUG carbamazepine therapy action BRAND unknown slightly shorter durations neuromuscular block may anticipated infusion rate requirements may higher.
112,"While the effects of chronic phenytoin or carbamazepine therapy on the action of MIVACRON are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher. ",carbamazepine,MIVACRON,effect,effects chronic phenytoin DRUG therapy action BRAND unknown slightly shorter durations neuromuscular block may anticipated infusion rate requirements may higher.
113,The authors report the case of an infant with confirmed congenital hypothyroidism on levothyroxine who experienced a possible drug interaction with simeticone. ,levothyroxine,simeticone,int,authors report case infant confirmed congenital hypothyroidism DRUG experienced possible drug interaction DRUG .
114,Do not exceed a 5 mg daily dose of VESIcare when administered with therapeutic doses of ketoconazole or other potent CYP3A4 inhibitors. ,VESIcare,ketoconazole,advise,exceed 5 mg daily dose BRAND administered therapeutic doses DRUG potent CYP3A4 inhibitors.
115,"Interaction with Guanethidine: Although minoxidil does not itself cause orthostatic hypotension, its administration to patients already receiving guanethidine can result in profound orthostatic effects. ",minoxidil,guanethidine,effect,Interaction Guanethidine: Although DRUG cause orthostatic hypotension administration patients already receiving DRUG result profound orthostatic effects.
116,If at all possible guanethidine should be discontinued well before minoxidil is begun. ,guanethidine,minoxidil,advise,possible DRUG discontinued well DRUG begun.
117,"While co-administration of ZAVESCA    appeared to increase the clearance of Cerezyme by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of Cerezyme. ",ZAVESCA,Cerezyme,mechanism,co administration BRAND appeared increase clearance BRAND 70% results conclusive small number subjects studied patients took variable doses Cerezyme.
118,Combination therapy with Cerezyme    (imiglucerase) and ZAVESCA    is not indicated.,Cerezyme,ZAVESCA,advise,Combination therapy BRAND (imiglucerase) BRAND indicated.
119,Combination therapy with Cerezyme    (imiglucerase) and ZAVESCA    is not indicated.,imiglucerase,ZAVESCA,advise,Combination therapy Cerezyme ( DRUG ) BRAND indicated.
120,Aminoglutethimide administered concomitantly with depo-subQ provera 104 may significantly decrease the serum concentrations of MPA. ,Aminoglutethimide,depo-subQ provera 104,mechanism,DRUG administered concomitantly BRAND may significantly decrease serum concentrations MPA.
121,Thiazides may decrease arterial responsiveness to norepinephrine. ,Thiazides,norepinephrine,effect,GROUP may decrease arterial responsiveness DRUG .
122,Thiazide drugs may increase the responsiveness of tubocurarine. ,Thiazide drugs,tubocurarine,effect,GROUP may increase responsiveness DRUG .
123,"Lithium renal clearance is reduced by thiazides, increasing the risk of lithium toxicity. ",Lithium,thiazides,mechanism,DRUG renal clearance reduced GROUP increasing risk lithium toxicity.
124,Thiazides may add to or potentiate the action of other antihypertensive drugs. ,Thiazides,antihypertensive drugs,effect,GROUP may add potentiate action GROUP .
125,"Diuretics: Patients on diuretics, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of ACEON    Tablets therapy. ",diuretics,ACEON,effect,Diuretics: Patients GROUP especially started recently may occasionally experience excessive reduction blood pressure initiation BRAND Tablets therapy.
126,The possibility of hypotensive effects can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with perindopril. ,diuretic,perindopril,effect,possibility hypotensive effects minimized either discontinuing GROUP increasing salt intake prior initiation treatment DRUG .
127,"If diuretics cannot be interrupted, close medical supervision should be provided with the first dose of ACEON    Tablets, for at least two hours and until blood pressure has stabilized for another hour. ",diuretics,ACEON,advise,GROUP cannot interrupted close medical supervision provided first dose BRAND Tablets least two hours blood pressure stabilized another hour.
128,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. ",digoxin,perindopril,mechanism,Digoxin: controlled pharmacokinetic study shown effect plasma digoxin concentrations coadministered ACEON Tablets effect DRUG plasma concentration DRUG /perindoprilat excluded.
129,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. ",digoxin,perindoprilat,mechanism,Digoxin: controlled pharmacokinetic study shown effect plasma digoxin concentrations coadministered ACEON Tablets effect DRUG plasma concentration perindopril/ DRUG_N excluded.
130,Gentamicin: Animal data have suggested the possibility of interaction between perindopril and gentamicin. ,perindopril,gentamicin,int,Gentamicin: Animal data suggested possibility interaction DRUG DRUG .
131,Concurrent use of alcohol and other CNS depression-producing drugs may increase the CNS depressant effects of methyprylon or these other medications.,alcohol,methyprylon,effect,Concurrent use DRUG CNS depression producing drugs may increase CNS depressant effects DRUG medications.
132,Concurrent use of alcohol and other CNS depression-producing drugs may increase the CNS depressant effects of methyprylon or these other medications.,CNS depression-producing drugs,methyprylon,effect,Concurrent use alcohol GROUP may increase CNS depressant effects DRUG medications.
133,Administration of valproic acid decreases oral clearance of temozolomide by about 5%. ,valproic acid,temozolomide,mechanism,Administration DRUG decreases oral clearance DRUG 5%.
134,"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. ",tolbutamide,teniposide,mechanism,study 34 different drugs tested therapeutically relevant concentrations DRUG sodium salicylate sulfamethizole displaced protein bound DRUG fresh human serum small significant extent.
135,"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. ",sodium salicylate,teniposide,mechanism,study 34 different drugs tested therapeutically relevant concentrations tolbutamide DRUG sulfamethizole displaced protein bound DRUG fresh human serum small significant extent.
136,"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. ",sulfamethizole,teniposide,mechanism,study 34 different drugs tested therapeutically relevant concentrations tolbutamide sodium salicylate DRUG displaced protein bound DRUG fresh human serum small significant extent.
137,An increase in intracellular levels of methotrexate was observed in vitro in the presence of teniposide.,methotrexate,teniposide,mechanism,increase intracellular levels DRUG observed vitro presence DRUG .
138,Anticoagulants (oral): The activity of oral anticoagulants may be potentiated by anti-vitamin-K activity attributed to methimazole.    ,anticoagulants,methimazole,effect,Anticoagulants (oral): activity oral GROUP may potentiated anti vitamin K activity attributed DRUG .
139,"Systemic and apparent oral midazolam clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20). ",midazolam,cyclosporine,mechanism,Systemic apparent oral DRUG clearance 24% (269 73 vs. 354 102 ml/min P = 0.022) 31% (479 190 vs. 688 265 ml/min P = 0.013) respectively lower DRUG treated patients (n = 20) matched tacrolimus treated patients (n = 20).
140,Decreased seizure threshold has been reported in patients receiving CYLERT concomitantly with antiepileptic medications.,CYLERT,antiepileptic medications,effect,Decreased seizure threshold reported patients receiving BRAND concomitantly GROUP .
141,Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.,Implanon,antiretroviral,effect,BRAND failure HIV positive woman GROUP therapy resulting two ectopic pregnancies.
142,We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.,antiretroviral,Implanon,effect,present interesting case HIV positive woman GROUP therapy tubal pregnancies two separate occasions BRAND place.
143,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,amantadine,effect,following agents may increase certain actions side effects GROUP : DRUG antiarrhythmic agents class (e.g. quinidine) antihistamines antipsychotic agents (e.g. phenothiazines) benzodiazepines MAO inhibitors narcotic analgesics (e.g. meperidine) nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity.
144,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,antiarrhythmic agents of class I,effect,following agents may increase certain actions side effects GROUP : amantadine GROUP (e.g. quinidine) antihistamines antipsychotic agents (e.g. phenothiazines) benzodiazepines MAO inhibitors narcotic analgesics (e.g. meperidine) nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity.
145,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,quinidine,effect,following agents may increase certain actions side effects GROUP : amantadine antiarrhythmic agents class (e.g. DRUG ) antihistamines antipsychotic agents (e.g. phenothiazines) benzodiazepines MAO inhibitors narcotic analgesics (e.g. meperidine) nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity.
146,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,antihistamines,effect,following agents may increase certain actions side effects GROUP : amantadine antiarrhythmic agents class (e.g. quinidine) GROUP antipsychotic agents (e.g. phenothiazines) benzodiazepines MAO inhibitors narcotic analgesics (e.g. meperidine) nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity.
147,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,antipsychotic agents,effect,following agents may increase certain actions side effects GROUP : amantadine antiarrhythmic agents class (e.g. quinidine) antihistamines GROUP (e.g. phenothiazines) benzodiazepines MAO inhibitors narcotic analgesics (e.g. meperidine) nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity.
148,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,phenothiazines,effect,following agents may increase certain actions side effects GROUP : amantadine antiarrhythmic agents class (e.g. quinidine) antihistamines antipsychotic agents (e.g. GROUP ) benzodiazepines MAO inhibitors narcotic analgesics (e.g. meperidine) nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity.
149,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,benzodiazepines,effect,following agents may increase certain actions side effects GROUP : amantadine antiarrhythmic agents class (e.g. quinidine) antihistamines antipsychotic agents (e.g. phenothiazines) GROUP MAO inhibitors narcotic analgesics (e.g. meperidine) nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity.
150,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,MAO inhibitors,effect,following agents may increase certain actions side effects GROUP : amantadine antiarrhythmic agents class (e.g. quinidine) antihistamines antipsychotic agents (e.g. phenothiazines) benzodiazepines GROUP narcotic analgesics (e.g. meperidine) nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity.
151,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,narcotic analgesics,effect,following agents may increase certain actions side effects GROUP : amantadine antiarrhythmic agents class (e.g. quinidine) antihistamines antipsychotic agents (e.g. phenothiazines) benzodiazepines MAO inhibitors GROUP (e.g. meperidine) nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity.
152,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,meperidine,effect,following agents may increase certain actions side effects GROUP : amantadine antiarrhythmic agents class (e.g. quinidine) antihistamines antipsychotic agents (e.g. phenothiazines) benzodiazepines MAO inhibitors narcotic analgesics (e.g. DRUG ) nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity.
153,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,nitrates,effect,following agents may increase certain actions side effects GROUP : amantadine antiarrhythmic agents class (e.g. quinidine) antihistamines antipsychotic agents (e.g. phenothiazines) benzodiazepines MAO inhibitors narcotic analgesics (e.g. meperidine) GROUP nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity.
154,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,nitrites,effect,following agents may increase certain actions side effects GROUP : amantadine antiarrhythmic agents class (e.g. quinidine) antihistamines antipsychotic agents (e.g. phenothiazines) benzodiazepines MAO inhibitors narcotic analgesics (e.g. meperidine) nitrates GROUP sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity.
155,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,sympathomimetic agents,effect,following agents may increase certain actions side effects GROUP : amantadine antiarrhythmic agents class (e.g. quinidine) antihistamines antipsychotic agents (e.g. phenothiazines) benzodiazepines MAO inhibitors narcotic analgesics (e.g. meperidine) nitrates nitrites GROUP tricyclic antidepressants drugs anticholinergic activity.
156,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,tricyclic antidepressants,effect,following agents may increase certain actions side effects GROUP : amantadine antiarrhythmic agents class (e.g. quinidine) antihistamines antipsychotic agents (e.g. phenothiazines) benzodiazepines MAO inhibitors narcotic analgesics (e.g. meperidine) nitrates nitrites sympathomimetic agents GROUP drugs anticholinergic activity.
157,Anticholinergics antagonize the effects of antiglaucoma agents. ,Anticholinergics,antiglaucoma agents,effect,GROUP antagonize effects GROUP .
158,Anticholinergic drugs in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as corticosteroids. ,Anticholinergic drugs,corticosteroids,effect,GROUP presence increased intraocular pressure may hazardous taken concurrently agents GROUP .
159,"Anticholinergic agents may affect gastrointestinal absorption of various drugs, such as slowly dissolving dosage forms of digoxin; ",Anticholinergic agents,digoxin,mechanism,GROUP may affect gastrointestinal absorption various drugs slowly dissolving dosage forms DRUG ;
160,"Anticholinergic drugs may antagonize the effects of drugs that alter gastrointestinal motility, such as metoclopramide. ",Anticholinergic drugs,metoclopramide,effect,GROUP may antagonize effects drugs alter gastrointestinal motility DRUG .
161,"Because antacids may interfere with the absorption of anticholinergic agents, simultaneous use of these drugs should be avoided. ",antacids,anticholinergic agents,mechanism,GROUP may interfere absorption GROUP simultaneous use drugs avoided.
162,"Ropivacaine should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics, since the toxic effects of these drugs are additive. ",Ropivacaine,anesthetics,advise,DRUG used caution patients receiving local GROUP agents structurally related amide type local anesthetics since toxic effects drugs additive.
163,"In vivo, the plasma clearance of ropivacaine was reduced by 70% during coadministration of fluvoxamine (25 mg bid for 2 days), a selective and potent CYP1A2 inhibitor. ",ropivacaine,fluvoxamine,mechanism,vivo plasma clearance DRUG reduced 70% coadministration DRUG (25 mg bid 2 days) selective potent CYP1A2 inhibitor.
164,"Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased ropivacaine plasma levels. ",fluvoxamine,Ropivacaine,int,Thus strong inhibitors cytochrome P4501A2 DRUG given concomitantly administration DRUG interact Ropivacaine leading increased ropivacaine plasma levels.
165,"Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.",ketoconazole,ropivacaine,mechanism,Coadministration selective potent inhibitor CYP3A4 DRUG (100 mg bid 2 days ropivacaine infusion administered 1 hour ketoconazole) caused 15% reduction vivo plasma clearance DRUG .
166,It has been reported that sulfamethoxazole may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin. ,sulfamethoxazole,warfarin,effect,reported DRUG may prolong prothrombin time patients receiving anticoagulant DRUG .
167,Sulfamethoxazole may inhibit the hepatic metabolism of phenytoin. ,Sulfamethoxazole,phenytoin,mechanism,DRUG may inhibit hepatic metabolism DRUG .
168,"At a 1.6-g dose, sulfamethoxazole produced a slight but significant increase in the half-life of phenytoin but did not produce a corresponding decrease in the metabolic clearance rate. ",sulfamethoxazole,phenytoin,mechanism,1.6 g dose DRUG produced slight significant increase half life DRUG produce corresponding decrease metabolic clearance rate.
169,"Sulfonamides can also displace methotrexate from plasma protein-binding sites, thus increasing free methotrexate concentrations. ",Sulfonamides,methotrexate,mechanism,GROUP also displace DRUG plasma protein binding sites thus increasing free methotrexate concentrations.
170,There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine. ,PURINETHOL,TABLOID,effect,usually complete cross resistance BRAND (mercaptopurine) BRAND brand Thioguanine.
171,There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine. ,PURINETHOL,Thioguanine,effect,usually complete cross resistance BRAND (mercaptopurine) TABLOID brand DRUG .
172,There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine. ,mercaptopurine,TABLOID,effect,usually complete cross resistance PURINETHOL ( DRUG ) BRAND brand Thioguanine.
173,There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine. ,mercaptopurine,Thioguanine,effect,usually complete cross resistance PURINETHOL ( DRUG ) TABLOID brand DRUG .
174,"As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    ",aminosalicylate derivatives,thioguanine,mechanism,vitro evidence GROUP (e.g. olsalazine mesalazine sulphasalazine) inhibit TPMT enzyme administered caution patients receiving concurrent DRUG therapy.
175,"As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    ",olsalazine,thioguanine,mechanism,vitro evidence aminosalicylate derivatives (e.g. DRUG mesalazine sulphasalazine) inhibit TPMT enzyme administered caution patients receiving concurrent DRUG therapy.
176,"As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    ",mesalazine,thioguanine,mechanism,vitro evidence aminosalicylate derivatives (e.g. olsalazine DRUG sulphasalazine) inhibit TPMT enzyme administered caution patients receiving concurrent DRUG therapy.
177,"As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    ",sulphasalazine,thioguanine,mechanism,vitro evidence aminosalicylate derivatives (e.g. olsalazine mesalazine DRUG ) inhibit TPMT enzyme administered caution patients receiving concurrent DRUG therapy.
178,"Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine. ",Thalidomide,barbiturates,effect,DRUG reported enhance sedative activity GROUP alcohol chlorpromazine reserpine.
179,John's Wort with hormonal contraceptive agents may reduce the effectiveness of the contraception and up to one month after discontinuation of these concomitant therapies. ,John's Wort,hormonal contraceptive agents,effect,DRUG_N GROUP may reduce effectiveness contraception one month discontinuation concomitant therapies.
180,"The CNS-depressant effect of propoxyphene is additive with that of other CNS depressants, including alcohol. ",propoxyphene,CNS depressants,effect,CNS depressant effect DRUG additive GROUP including alcohol.
181,"The CNS-depressant effect of propoxyphene is additive with that of other CNS depressants, including alcohol. ",propoxyphene,alcohol,effect,CNS depressant effect DRUG additive CNS depressants including DRUG .
182,"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast. ",phenobarbital,montelukast,advise,reasonable employ appropriate clinical monitoring potent cytochrome P450 enzyme inducers DRUG rifampin co administered DRUG .
183,"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast. ",rifampin,montelukast,advise,reasonable employ appropriate clinical monitoring potent cytochrome P450 enzyme inducers phenobarbital DRUG co administered DRUG .
184,"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.",phenobarbital,montelukast,advise,reasonable employ appropriate clinical monitoring potent cytochrome P450 enzyme inducers DRUG rifampin co administered DRUG .
185,"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.",rifampin,montelukast,advise,reasonable employ appropriate clinical monitoring potent cytochrome P450 enzyme inducers phenobarbital DRUG co administered DRUG .
186,"Cimetidine: Cimetidine, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in pramipexole AUC and a 40% increase in half-life (N= 12). ",Cimetidine,pramipexole,mechanism,Cimetidine: DRUG known inhibitor renal tubular secretion organic bases via cationic transport system caused 50% increase DRUG AUC 40% increase half life (N= 12).
187,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",cimetidine,pramipexole,mechanism,drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system (e.g. DRUG ranitidine diltiazem triamterene verapamil quinidine quinine) decreases oral clearance DRUG 20% secreted anionic transport system (e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide) likely little effect oral clearance pramipexole.
188,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",ranitidine,pramipexole,mechanism,drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system (e.g. cimetidine DRUG diltiazem triamterene verapamil quinidine quinine) decreases oral clearance DRUG 20% secreted anionic transport system (e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide) likely little effect oral clearance pramipexole.
189,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",diltiazem,pramipexole,mechanism,drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system (e.g. cimetidine ranitidine DRUG triamterene verapamil quinidine quinine) decreases oral clearance DRUG 20% secreted anionic transport system (e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide) likely little effect oral clearance pramipexole.
190,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",triamterene,pramipexole,mechanism,drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system (e.g. cimetidine ranitidine diltiazem DRUG verapamil quinidine quinine) decreases oral clearance DRUG 20% secreted anionic transport system (e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide) likely little effect oral clearance pramipexole.
191,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",verapamil,pramipexole,mechanism,drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system (e.g. cimetidine ranitidine diltiazem triamterene DRUG quinidine quinine) decreases oral clearance DRUG 20% secreted anionic transport system (e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide) likely little effect oral clearance pramipexole.
192,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",quinidine,pramipexole,mechanism,drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system (e.g. cimetidine ranitidine diltiazem triamterene verapamil DRUG quinine) decreases oral clearance DRUG 20% secreted anionic transport system (e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide) likely little effect oral clearance pramipexole.
193,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",quinine,pramipexole,mechanism,drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system (e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine DRUG ) decreases oral clearance DRUG 20% secreted anionic transport system (e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide) likely little effect oral clearance pramipexole.
194,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",cephalosporins,pramipexole,mechanism,drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system (e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine) decreases oral clearance pramipexole 20% secreted anionic transport system (e.g. GROUP penicillins indomethacin hydrochlorothiazide chlorpropamide) likely little effect oral clearance DRUG .
195,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",penicillins,pramipexole,mechanism,drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system (e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine) decreases oral clearance pramipexole 20% secreted anionic transport system (e.g. cephalosporins GROUP indomethacin hydrochlorothiazide chlorpropamide) likely little effect oral clearance DRUG .
196,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",indomethacin,pramipexole,mechanism,drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system (e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine) decreases oral clearance pramipexole 20% secreted anionic transport system (e.g. cephalosporins penicillins DRUG hydrochlorothiazide chlorpropamide) likely little effect oral clearance DRUG .
197,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",hydrochlorothiazide,pramipexole,mechanism,drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system (e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine) decreases oral clearance pramipexole 20% secreted anionic transport system (e.g. cephalosporins penicillins indomethacin DRUG chlorpropamide) likely little effect oral clearance DRUG .
198,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",chlorpropamide,pramipexole,mechanism,drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system (e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine) decreases oral clearance pramipexole 20% secreted anionic transport system (e.g. cephalosporins penicillins indomethacin hydrochlorothiazide DRUG ) likely little effect oral clearance DRUG .
199,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",dopamine antagonists,MIRAPEX,effect,Dopamine antagonists: Since pramipexole dopamine agonist possible GROUP neuroleptics (phenothiazines butyrophenones thioxanthenes) metoclopramide may diminish effectiveness BRAND .
200,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",neuroleptics,MIRAPEX,effect,Dopamine antagonists: Since pramipexole dopamine agonist possible dopamine antagonists GROUP (phenothiazines butyrophenones thioxanthenes) metoclopramide may diminish effectiveness BRAND .
201,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",phenothiazines,MIRAPEX,effect,Dopamine antagonists: Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics ( GROUP butyrophenones thioxanthenes) metoclopramide may diminish effectiveness BRAND .
202,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",butyrophenones,MIRAPEX,effect,Dopamine antagonists: Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics (phenothiazines GROUP thioxanthenes) metoclopramide may diminish effectiveness BRAND .
203,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",thioxanthenes,MIRAPEX,effect,Dopamine antagonists: Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics (phenothiazines butyrophenones GROUP ) metoclopramide may diminish effectiveness BRAND .
204,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",metoclopramide,MIRAPEX,effect,Dopamine antagonists: Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics (phenothiazines butyrophenones thioxanthenes) GROUP may diminish effectiveness BRAND .
205,"There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including pantoprazole, and warfarin concomitantly. ",proton pump inhibitors,warfarin,effect,postmarketing reports increased INR prothrombin time patients receiving GROUP including pantoprazole DRUG concomitantly.
206,"There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including pantoprazole, and warfarin concomitantly. ",pantoprazole,warfarin,effect,postmarketing reports increased INR prothrombin time patients receiving proton pump inhibitors including DRUG DRUG concomitantly.
207,Patients treated with proton pump inhibitors and warfarin concomitantly should be monitored for increases in INR and prothrombin time. ,proton pump inhibitors,warfarin,advise,Patients treated GROUP DRUG concomitantly monitored increases INR prothrombin time.
208,"Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts). ",pantoprazole,ketoconazole,mechanism,profound long lasting inhibition gastric acid secretion DRUG may interfere absorption drugs gastric pH important determinant bioavailability (eg DRUG ampicillin esters iron salts).
209,"Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts). ",pantoprazole,ampicillin,mechanism,profound long lasting inhibition gastric acid secretion DRUG may interfere absorption drugs gastric pH important determinant bioavailability (eg ketoconazole DRUG esters iron salts).
210,"Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts). ",pantoprazole,iron,mechanism,profound long lasting inhibition gastric acid secretion DRUG may interfere absorption drugs gastric pH important determinant bioavailability (eg ketoconazole ampicillin esters DRUG salts).
211,Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.,sunitinib,docetaxel,int,Synergistic interaction DRUG DRUG sequence dependent human non small lung cancer EGFR TKIs resistant mutation.
212,"Although single or concurrent use of sunitinib and docetaxel has some anti-proliferative effects, the sequential administrations of both drugs remarkably enhanced anti-tumor activity. ",sunitinib,docetaxel,effect,Although single concurrent use DRUG DRUG anti proliferative effects sequential administrations drugs remarkably enhanced anti tumor activity.
213,"When cells were exposed to docetaxel followed by sunitinib, synergism was observed. ",docetaxel,sunitinib,effect,cells exposed DRUG followed DRUG synergism observed.
214,The molecular basis of this synergism is that the signaling pathways that were initially activated by docetaxel exposure were efficiently suppressed by the subsequent exposure to sunitinib. ,docetaxel,sunitinib,effect,molecular basis synergism signaling pathways initially activated DRUG exposure efficiently suppressed subsequent exposure DRUG .
215,Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.,docetaxel,sunitinib,effect,Sunitinib single agent exhibits anti proliferative effects vitro NSCLC cell lines EGFR T790M K ras mutations sequential administration DRUG followed DRUG superior sunitinib followed docetaxel concurrent administration.
216,Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir. ,Ethanol,abacavir,mechanism,DRUG decreases elimination DRUG causing increase overall exposure . addition methadone clinically significant effect pharmacokinetic properties abacavir.
217,"In a study of 11 HIV-infected patients receiving methadone-maintenance therapy (40 mg and 90 mg daily) with 600 mg of ZIAGEN twice daily (twice the currently recommended dose), oral methadone clearance increased 22% (90% CI 6% to 42%). ",methadone,ZIAGEN,mechanism,study 11 HIV infected patients receiving DRUG maintenance therapy (40 mg 90 mg daily) 600 mg BRAND twice daily (twice currently recommended dose) oral methadone clearance increased 22% (90% CI 6% 42%).
218,"Sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics. ",Sulfoxone,barbiturates,effect,DRUG may increase effects GROUP tolbutamide uricosurics.
219,"Sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics. ",Sulfoxone,tolbutamide,effect,DRUG may increase effects barbiturates DRUG uricosurics.
220,"Sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics. ",Sulfoxone,uricosurics,effect,DRUG may increase effects barbiturates tolbutamide GROUP .
221,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ",Phenothiazines,CNS depressants,effect,GROUP capable potentiating GROUP (e.g. barbiturates anesthetics opiates alcohol etc.)
222,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ",Phenothiazines,barbiturates,effect,GROUP capable potentiating CNS depressants (e.g. GROUP anesthetics opiates alcohol etc.)
223,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ",Phenothiazines,anesthetics,effect,GROUP capable potentiating CNS depressants (e.g. barbiturates GROUP opiates alcohol etc.)
224,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ",Phenothiazines,opiates,effect,GROUP capable potentiating CNS depressants (e.g. barbiturates anesthetics GROUP alcohol etc.)
225,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ",Phenothiazines,alcohol,effect,GROUP capable potentiating CNS depressants (e.g. barbiturates anesthetics opiates DRUG etc.)
226,A pharmacokinetic study demonstrated that coadministration of megestrol acetate and indinavir results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of indinavir. ,megestrol acetate,indinavir,mechanism,pharmacokinetic study demonstrated coadministration DRUG DRUG results significant decrease pharmacokinetic parameters (~36% Cmax ~28% AUC) indinavir.
227,Administration of a higher dose of indinavir should be considered when coadministering with megestrol acetate. ,indinavir,megestrol acetate,advise,Administration higher dose DRUG considered coadministering DRUG .
228,Streptozocin has been reported to prolong the elimination half-life of doxorubicin and may lead to severe bone marrow suppression; ,Streptozocin,doxorubicin,mechanism,DRUG reported prolong elimination half life DRUG may lead severe bone marrow suppression;
229,a reduction of the doxorubicin dosage should be considered in patients receiving ZANOSAR concurrently. ,doxorubicin,ZANOSAR,advise,reduction DRUG dosage considered patients receiving BRAND concurrently.
230,The concurrent use of streptozocin and phenytoin has been reported in one case to result in reduced streptozocin cytotoxicity.    ,streptozocin,phenytoin,effect,concurrent use DRUG DRUG reported one case result reduced streptozocin cytotoxicity.
231,"Sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics. ",Sulfamethizole,barbiturates,effect,DRUG may increase effects GROUP tolbutamide uricosurics.
232,"Sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics. ",Sulfamethizole,tolbutamide,effect,DRUG may increase effects barbiturates DRUG uricosurics.
233,"Sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics. ",Sulfamethizole,uricosurics,effect,DRUG may increase effects barbiturates tolbutamide GROUP .
234,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",Anticoagulants,TNKase,effect,GROUP (such heparin vitamin K antagonists) drugs alter platelet function (such acetylsalicylic acid dipyridamole GP IIb/IIIa inhibitors) may increase risk bleeding administered prior BRAND therapy.
235,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",heparin,TNKase,effect,Anticoagulants (such DRUG vitamin K antagonists) drugs alter platelet function (such acetylsalicylic acid dipyridamole GP IIb/IIIa inhibitors) may increase risk bleeding administered prior BRAND therapy.
236,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",vitamin K antagonists,TNKase,effect,Anticoagulants (such heparin GROUP ) drugs alter platelet function (such acetylsalicylic acid dipyridamole GP IIb/IIIa inhibitors) may increase risk bleeding administered prior BRAND therapy.
237,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",acetylsalicylic acid,TNKase,effect,Anticoagulants (such heparin vitamin K antagonists) drugs alter platelet function (such DRUG dipyridamole GP IIb/IIIa inhibitors) may increase risk bleeding administered prior BRAND therapy.
238,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",dipyridamole,TNKase,effect,Anticoagulants (such heparin vitamin K antagonists) drugs alter platelet function (such acetylsalicylic acid DRUG GP IIb/IIIa inhibitors) may increase risk bleeding administered prior BRAND therapy.
239,"When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine). ",rimantadine HCl,Cimetidine,mechanism,single 100 mg dose DRUG administered one hour initiation DRUG (300 mg four times day) apparent total rimantadine clearance single dose normal healthy adults reduced 18% (compared apparent total rimantadine clearance subjects absence cimetidine).
240,Coadministration with acetaminophen reduced the peak concentration and AUC values for rimantadine by approximately 11%. ,acetaminophen,rimantadine,mechanism,Coadministration DRUG reduced peak concentration AUC values DRUG approximately 11%.
241,Peak plasma concentrations and AUC of rimantadine were reduced approximately 10% in the presence of aspirin.,rimantadine,aspirin,mechanism,Peak plasma concentrations AUC DRUG reduced approximately 10% presence BRAND .
242,Trimethoprim may inhibit the hepatic metabolism of phenytoin. ,Trimethoprim,phenytoin,mechanism,DRUG may inhibit hepatic metabolism DRUG .
243,"Trimethoprim, given at a common clinical dosage, increased the phenytoin half-life by 51% and decreased the phenytoin metabolic clearance rate by 30%. ",Trimethoprim,phenytoin,mechanism,DRUG given common clinical dosage increased DRUG half life 51% decreased phenytoin metabolic clearance rate 30%.
244,"Trimethoprim, given at a common clinical dosage, increased the phenytoin half-life by 51% and decreased the phenytoin metabolic clearance rate by 30%. ",Trimethoprim,phenytoin,mechanism,DRUG given common clinical dosage increased phenytoin half life 51% decreased DRUG metabolic clearance rate 30%.
245,Pilocarpine should be administered with caution to patients taking beta adrenergic antagonists because of the possibility of conduction disturbances. ,Pilocarpine,beta adrenergic antagonists,advise,DRUG administered caution patients taking GROUP possibility conduction disturbances.
246,Mutual inhibition of metabolism occurs with concurrent use of cyclosporin and methylprednisolone; ,cyclosporin,methylprednisolone,mechanism,Mutual inhibition metabolism occurs concurrent use DRUG DRUG ;
247,convulsions have been reported with concurrent use of methylprednisolone and cyclosporin. ,methylprednisolone,cyclosporin,effect,convulsions reported concurrent use DRUG DRUG .
248,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",phenobarbital,methylprednisolone,mechanism,Drugs induce hepatic enzymes DRUG phenytoin rifampin may increase clearance DRUG may require increased methylprednisolone dose achieve desired response.
249,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",phenobarbital,methylprednisolone,advise,Drugs induce hepatic enzymes DRUG phenytoin rifampin may increase clearance methylprednisolone may require increased DRUG dose achieve desired response.
250,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",phenytoin,methylprednisolone,mechanism,Drugs induce hepatic enzymes phenobarbital DRUG rifampin may increase clearance DRUG may require increased methylprednisolone dose achieve desired response.
251,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",phenytoin,methylprednisolone,advise,Drugs induce hepatic enzymes phenobarbital DRUG rifampin may increase clearance methylprednisolone may require increased DRUG dose achieve desired response.
252,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",rifampin,methylprednisolone,mechanism,Drugs induce hepatic enzymes phenobarbital phenytoin DRUG may increase clearance DRUG may require increased methylprednisolone dose achieve desired response.
253,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",rifampin,methylprednisolone,advise,Drugs induce hepatic enzymes phenobarbital phenytoin DRUG may increase clearance methylprednisolone may require increased DRUG dose achieve desired response.
254,Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. ,troleandomycin,methylprednisolone,mechanism,Drugs DRUG ketoconazole may inhibit metabolism DRUG thus decrease clearance.
255,Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. ,ketoconazole,methylprednisolone,mechanism,Drugs troleandomycin DRUG may inhibit metabolism DRUG thus decrease clearance.
256,Methylprednisolone may increase the clearance of chronic high dose aspirin. ,Methylprednisolone,aspirin,mechanism,DRUG may increase clearance chronic high dose BRAND .
257,This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when methylprednisolone is withdrawn. ,salicylate,methylprednisolone,effect,could lead decreased salicylate serum levels increase risk GROUP toxicity DRUG withdrawn.
258,Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia. ,Aspirin,corticosteroids,advise,BRAND used cautiously conjunction GROUP patients suffering hypoprothrombinemia.
259,There are reports of enhanced as well as diminished effects of anticoagulant when given concurrently with corticosteroids. ,anticoagulant,corticosteroids,effect,reports enhanced well diminished effects GROUP given concurrently GROUP .
260,The effects of metoclopramide on gastrointestinal motility are antagonized by anticholinergic drugs and narcotic analgesics. ,metoclopramide,anticholinergic drugs,effect,effects DRUG gastrointestinal motility antagonized GROUP narcotic analgesics.
261,The effects of metoclopramide on gastrointestinal motility are antagonized by anticholinergic drugs and narcotic analgesics. ,metoclopramide,narcotic analgesics,effect,effects DRUG gastrointestinal motility antagonized anticholinergic drugs GROUP .
262,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",metoclopramide,alcohol,effect,Additive sedative effects occur DRUG given DRUG sedatives hypnotics narcotics tranquilizers.
263,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",metoclopramide,sedatives,effect,Additive sedative effects occur DRUG given alcohol GROUP hypnotics narcotics tranquilizers.
264,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",metoclopramide,hypnotics,effect,Additive sedative effects occur DRUG given alcohol sedatives GROUP narcotics tranquilizers.
265,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",metoclopramide,narcotics,effect,Additive sedative effects occur DRUG given alcohol sedatives hypnotics GROUP tranquilizers.
266,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",metoclopramide,tranquilizers,effect,Additive sedative effects occur DRUG given alcohol sedatives hypnotics narcotics GROUP .
267,"The finding that metoclopramide releases catecholamines in patients with essential hypertension suggests that it should be used cautiously, if at all, in patients receiving monoamine oxi-dase inhibitors. ",metoclopramide,monoamine oxi-dase inhibitors,advise,finding DRUG releases catecholamines patients essential hypertension suggests used cautiously patients receiving GROUP .
268,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",digoxin,metoclopramide,mechanism,Absorption drugs stomach may diminished (e.g. DRUG ) DRUG whereas rate and/or extent absorption drugs small bowel may increased (e.g. acetaminophen tetracycline levodopa ethanol cyclosporine).
269,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",metoclopramide,acetaminophen,mechanism,Absorption drugs stomach may diminished (e.g. digoxin) DRUG whereas rate and/or extent absorption drugs small bowel may increased (e.g. DRUG tetracycline levodopa ethanol cyclosporine).
270,"Because the action of metoclopramide will influence the delivery of food to the intestines and thus the rate of absorption, insulin dosage or timing of dosage may require adjustment.",metoclopramide,insulin,advise,action DRUG influence delivery food intestines thus rate absorption DRUG dosage timing dosage may require adjustment.
271,"Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all. ",Vasopressors,halothane,effect,GROUP particularly metaraminol may cause serious cardiac arrhythmias DRUG anesthesia therefore used great caution all.
272,"Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all. ",metaraminol,halothane,effect,Vasopressors particularly DRUG may cause serious cardiac arrhythmias DRUG anesthesia therefore used great caution all.
273,MAO Inhibitors: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). ,sympathomimetic pressor amines,monoamine oxidase inhibitors,effect,MAO Inhibitors: pressor effect GROUP markedly potentiated patients receiving GROUP (MAOI).
274,MAO Inhibitors: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). ,sympathomimetic pressor amines,MAOI,effect,MAO Inhibitors: pressor effect GROUP markedly potentiated patients receiving monoamine oxidase inhibitors ( GROUP ).
275,The pressor response of adrenergic agents may also be potentiated by tricyclic antidepressants.,adrenergic agents,tricyclic antidepressants,effect,pressor response GROUP may also potentiated GROUP .
276,"Concomitant use of omeprazole and clopidogrel was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by omeprazole of CYP2C19, a cytochrome P450 (CYP) enzyme. ",omeprazole,clopidogrel,mechanism,Concomitant use DRUG DRUG found decrease exposure (AUC) clopidogrel's active metabolite 50% sharply increase platelet reactivity result inhibition omeprazole CYP2C19 cytochrome P450 (CYP) enzyme.
277,Pantoprazole has a much weaker effect on clopidogrel's pharmacokinetics and on platelet reactivity during concomitant use. ,Pantoprazole,clopidogrel,mechanism,DRUG much weaker effect DRUG 's pharmacokinetics platelet reactivity concomitant use.
278,Regulatory agencies state that the combination of clopidogrel and the CYP2C19 inhibitors omeprazole and esomeprazole should be avoided. ,clopidogrel,omeprazole,advise,Regulatory agencies state combination DRUG CYP2C19 inhibitors DRUG esomeprazole avoided.
279,Regulatory agencies state that the combination of clopidogrel and the CYP2C19 inhibitors omeprazole and esomeprazole should be avoided. ,clopidogrel,esomeprazole,advise,Regulatory agencies state combination DRUG CYP2C19 inhibitors omeprazole DRUG avoided.
280,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,tricyclic,int,DRUG may interact antidepressants ( GROUP type) MAO inhibitors (e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone) quinidine amantadine antihistamines (e.g. diphenhydramine) anticholinergics potassium chloride supplements antacids absorbent type anti diarrhea medicines (e.g. kaolin pectin) phenothiazines (e.g. chlorpromazine promethazine).
281,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,MAO inhibitors,int,DRUG may interact antidepressants (tricyclic type) GROUP (e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone) quinidine amantadine antihistamines (e.g. diphenhydramine) anticholinergics potassium chloride supplements antacids absorbent type anti diarrhea medicines (e.g. kaolin pectin) phenothiazines (e.g. chlorpromazine promethazine).
282,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,phenelzine,int,DRUG may interact antidepressants (tricyclic type) MAO inhibitors (e.g. DRUG linezolid tranylcypromine isocarboxazid selegiline furazolidone) quinidine amantadine antihistamines (e.g. diphenhydramine) anticholinergics potassium chloride supplements antacids absorbent type anti diarrhea medicines (e.g. kaolin pectin) phenothiazines (e.g. chlorpromazine promethazine).
283,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,linezolid,int,DRUG may interact antidepressants (tricyclic type) MAO inhibitors (e.g. phenelzine DRUG tranylcypromine isocarboxazid selegiline furazolidone) quinidine amantadine antihistamines (e.g. diphenhydramine) anticholinergics potassium chloride supplements antacids absorbent type anti diarrhea medicines (e.g. kaolin pectin) phenothiazines (e.g. chlorpromazine promethazine).
284,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,tranylcypromine,int,DRUG may interact antidepressants (tricyclic type) MAO inhibitors (e.g. phenelzine linezolid DRUG isocarboxazid selegiline furazolidone) quinidine amantadine antihistamines (e.g. diphenhydramine) anticholinergics potassium chloride supplements antacids absorbent type anti diarrhea medicines (e.g. kaolin pectin) phenothiazines (e.g. chlorpromazine promethazine).
285,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,isocarboxazid,int,DRUG may interact antidepressants (tricyclic type) MAO inhibitors (e.g. phenelzine linezolid tranylcypromine DRUG selegiline furazolidone) quinidine amantadine antihistamines (e.g. diphenhydramine) anticholinergics potassium chloride supplements antacids absorbent type anti diarrhea medicines (e.g. kaolin pectin) phenothiazines (e.g. chlorpromazine promethazine).
286,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,selegiline,int,DRUG may interact antidepressants (tricyclic type) MAO inhibitors (e.g. phenelzine linezolid tranylcypromine isocarboxazid DRUG furazolidone) quinidine amantadine antihistamines (e.g. diphenhydramine) anticholinergics potassium chloride supplements antacids absorbent type anti diarrhea medicines (e.g. kaolin pectin) phenothiazines (e.g. chlorpromazine promethazine).
287,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,furazolidone,int,DRUG may interact antidepressants (tricyclic type) MAO inhibitors (e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline DRUG ) quinidine amantadine antihistamines (e.g. diphenhydramine) anticholinergics potassium chloride supplements antacids absorbent type anti diarrhea medicines (e.g. kaolin pectin) phenothiazines (e.g. chlorpromazine promethazine).
288,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,quinidine,int,DRUG may interact antidepressants (tricyclic type) MAO inhibitors (e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone) DRUG amantadine antihistamines (e.g. diphenhydramine) anticholinergics potassium chloride supplements antacids absorbent type anti diarrhea medicines (e.g. kaolin pectin) phenothiazines (e.g. chlorpromazine promethazine).
289,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,amantadine,int,DRUG may interact antidepressants (tricyclic type) MAO inhibitors (e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone) quinidine DRUG antihistamines (e.g. diphenhydramine) anticholinergics potassium chloride supplements antacids absorbent type anti diarrhea medicines (e.g. kaolin pectin) phenothiazines (e.g. chlorpromazine promethazine).
290,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,antihistamines,int,DRUG may interact antidepressants (tricyclic type) MAO inhibitors (e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone) quinidine amantadine GROUP (e.g. diphenhydramine) anticholinergics potassium chloride supplements antacids absorbent type anti diarrhea medicines (e.g. kaolin pectin) phenothiazines (e.g. chlorpromazine promethazine).
291,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,diphenhydramine,int,DRUG may interact antidepressants (tricyclic type) MAO inhibitors (e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone) quinidine amantadine antihistamines (e.g. DRUG ) anticholinergics potassium chloride supplements antacids absorbent type anti diarrhea medicines (e.g. kaolin pectin) phenothiazines (e.g. chlorpromazine promethazine).
292,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,anticholinergics,int,DRUG may interact antidepressants (tricyclic type) MAO inhibitors (e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone) quinidine amantadine antihistamines (e.g. diphenhydramine) GROUP potassium chloride supplements antacids absorbent type anti diarrhea medicines (e.g. kaolin pectin) phenothiazines (e.g. chlorpromazine promethazine).
293,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,potassium chloride,int,DRUG may interact antidepressants (tricyclic type) MAO inhibitors (e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone) quinidine amantadine antihistamines (e.g. diphenhydramine) anticholinergics DRUG supplements antacids absorbent type anti diarrhea medicines (e.g. kaolin pectin) phenothiazines (e.g. chlorpromazine promethazine).
294,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,antacids,int,DRUG may interact antidepressants (tricyclic type) MAO inhibitors (e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone) quinidine amantadine antihistamines (e.g. diphenhydramine) anticholinergics potassium chloride supplements GROUP absorbent type anti diarrhea medicines (e.g. kaolin pectin) phenothiazines (e.g. chlorpromazine promethazine).
295,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,absorbent-type anti-diarrhea medicines,int,DRUG may interact antidepressants (tricyclic type) MAO inhibitors (e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone) quinidine amantadine antihistamines (e.g. diphenhydramine) anticholinergics potassium chloride supplements antacids GROUP (e.g. kaolin pectin) phenothiazines (e.g. chlorpromazine promethazine).
296,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,kaolin,int,DRUG may interact antidepressants (tricyclic type) MAO inhibitors (e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone) quinidine amantadine antihistamines (e.g. diphenhydramine) anticholinergics potassium chloride supplements antacids absorbent type anti diarrhea medicines (e.g. DRUG pectin) phenothiazines (e.g. chlorpromazine promethazine).
297,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,pectin,int,DRUG may interact antidepressants (tricyclic type) MAO inhibitors (e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone) quinidine amantadine antihistamines (e.g. diphenhydramine) anticholinergics potassium chloride supplements antacids absorbent type anti diarrhea medicines (e.g. kaolin DRUG ) phenothiazines (e.g. chlorpromazine promethazine).
298,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,phenothiazines,int,DRUG may interact antidepressants (tricyclic type) MAO inhibitors (e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone) quinidine amantadine antihistamines (e.g. diphenhydramine) anticholinergics potassium chloride supplements antacids absorbent type anti diarrhea medicines (e.g. kaolin pectin) GROUP (e.g. chlorpromazine promethazine).
299,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,chlorpromazine,int,DRUG may interact antidepressants (tricyclic type) MAO inhibitors (e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone) quinidine amantadine antihistamines (e.g. diphenhydramine) anticholinergics potassium chloride supplements antacids absorbent type anti diarrhea medicines (e.g. kaolin pectin) phenothiazines (e.g. DRUG promethazine).
300,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,promethazine,int,DRUG may interact antidepressants (tricyclic type) MAO inhibitors (e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone) quinidine amantadine antihistamines (e.g. diphenhydramine) anticholinergics potassium chloride supplements antacids absorbent type anti diarrhea medicines (e.g. kaolin pectin) phenothiazines (e.g. chlorpromazine DRUG ).
301,The preclinical combination of lenalidomide with the mTOR inhibitor CCI-779 has displayed synergy in vitro and represents a novel combination in MM.,lenalidomide,CCI-779,effect,preclinical combination DRUG mTOR inhibitor DRUG displayed synergy vitro represents novel combination MM.
302,"The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). ",ticagrelor,aspirin,effect,FDA approved DRUG (Brilinta AstraZeneca) oral antiplatelet drug use low dose BRAND reduce rate thrombotic cardiovascular events patients acute coronary syndrome (ACS).
303,"The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). ",Brilinta,aspirin,effect,FDA approved ticagrelor ( BRAND AstraZeneca) oral antiplatelet drug use low dose BRAND reduce rate thrombotic cardiovascular events patients acute coronary syndrome (ACS).
304,"Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine.
",S-ketamine,ticlopidine,effect,Exposure oral DRUG unaffected itraconazole greatly increased DRUG .
305,"Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine. ",Ticlopidine,ketamine,mechanism,DRUG treatment increased mean area plasma concentration time curve extrapolated infinity (AUC(0 )) oral DRUG 2.4 fold whereas itraconazole treatment increase exposure ketamine.
306,The findings suggest that the dosage of S-ketamine should be reduced in patients receiving ticlopidine.,S-ketamine,ticlopidine,advise,findings suggest dosage DRUG reduced patients receiving DRUG .
307,Patients receiving antibiotics and sulfonamides generally should not be treated with ganglion blockers.  ,antibiotics,ganglion blockers,advise,Patients receiving GROUP sulfonamides generally treated GROUP .
308,Patients receiving antibiotics and sulfonamides generally should not be treated with ganglion blockers.  ,sulfonamides,ganglion blockers,advise,Patients receiving antibiotics GROUP generally treated GROUP .
309,"The action of Mecamylamine may be potentiated by anesthesia, other antihypertensive drugs and alcohol.",Mecamylamine,antihypertensive drugs,effect,action DRUG may potentiated anesthesia GROUP alcohol.
310,"The action of Mecamylamine may be potentiated by anesthesia, other antihypertensive drugs and alcohol.",Mecamylamine,alcohol,effect,action DRUG may potentiated anesthesia antihypertensive drugs DRUG .
311,"Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time. ",metronidazole,coumarin,effect,Oral DRUG reported potentiate anticoagulant effect GROUP warfarin resulting prolongation prothrombin time.
312,"Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time. ",metronidazole,warfarin,effect,Oral DRUG reported potentiate anticoagulant effect coumarin DRUG resulting prolongation prothrombin time.
313,Concomitant use of alcohol with phentermine hydrochloride may result in an adverse drug interaction.,alcohol,phentermine hydrochloride,int,Concomitant use DRUG DRUG may result adverse drug interaction.
314,Other short-acting beta adrenergic aerosol bronchodilators should not be used concomitantly with MAXAIR AUTOHALER because they may have additive effects.,short-acting beta adrenergic aerosol bronchodilators,MAXAIR AUTOHALER,advise,GROUP used concomitantly BRAND may additive effects.
315,A study published in 2002 found that vigabatrin causes a statistically significant increase in plasma clearance of carbamazepine. ,vigabatrin,carbamazepine,mechanism,study published 2002 found DRUG causes statistically significant increase plasma clearance DRUG .
316,"In 1984, Drs Rimmer and Richens at the University of Wales reported that administering vigabatrin with phenytoin lowered the serum phenytoin concentration in patients with treatment-resistant epilepsy. ",vigabatrin,phenytoin,mechanism,1984 Drs Rimmer Richens University Wales reported administering DRUG DRUG lowered serum phenytoin concentration patients treatment resistant epilepsy.
317,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",phenobarbital,corticosteroids,mechanism,Drugs induce hepatic enzymes DRUG phenytoin rifampin may increase clearance GROUP may require increases corticosteroid dose achieve desired response.
318,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",phenobarbital,corticosteroid,mechanism,Drugs induce hepatic enzymes DRUG phenytoin rifampin may increase clearance corticosteroids may require increases GROUP dose achieve desired response.
319,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",phenytoin,corticosteroids,mechanism,Drugs induce hepatic enzymes phenobarbital DRUG rifampin may increase clearance GROUP may require increases corticosteroid dose achieve desired response.
320,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",phenytoin,corticosteroid,mechanism,Drugs induce hepatic enzymes phenobarbital DRUG rifampin may increase clearance corticosteroids may require increases GROUP dose achieve desired response.
321,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",rifampin,corticosteroids,mechanism,Drugs induce hepatic enzymes phenobarbital phenytoin DRUG may increase clearance GROUP may require increases corticosteroid dose achieve desired response.
322,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",rifampin,corticosteroid,mechanism,Drugs induce hepatic enzymes phenobarbital phenytoin DRUG may increase clearance corticosteroids may require increases GROUP dose achieve desired response.
323,Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance. ,troleandomycin,corticosteroids,mechanism,Drugs DRUG ketoconazole may inhibit metabolism GROUP thus decrease clearance.
324,Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance. ,ketoconazole,corticosteroids,mechanism,Drugs troleandomycin DRUG may inhibit metabolism GROUP thus decrease clearance.
325,Corticosteroids may increase the clearance of chronic high dose aspirin. ,Corticosteroids,aspirin,mechanism,GROUP may increase clearance chronic high dose BRAND .
326,This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn. ,salicylate,corticosteroid,effect,could lead decreased salicylate serum levels increase risk GROUP toxicity GROUP withdrawn.
327,Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia. ,Aspirin,corticosteroids,advise,BRAND used cautiously conjunction GROUP patients suffering hypoprothrombinemia.
328,The effect of corticosteroids on oral anticoagulants is variable. ,corticosteroids,anticoagulants,effect,effect GROUP oral GROUP variable.
329,There are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids. ,anticoagulants,corticosteroids,effect,reports enhanced well diminished effects GROUP given concurrently GROUP .
330,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",Vitamin B1,Loop Diuretics,int,Interactions DRUG (Thiamine): GROUP Oral Contraceptives Stavudine Tricyclic Antidepressants
331,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",Vitamin B1,Contraceptives,int,Interactions DRUG (Thiamine): Loop Diuretics Oral GROUP Stavudine Tricyclic Antidepressants
332,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",Vitamin B1,Stavudine,int,Interactions DRUG (Thiamine): Loop Diuretics Oral Contraceptives DRUG Tricyclic Antidepressants
333,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",Vitamin B1,Tricyclic Antidepressants,int,Interactions DRUG (Thiamine): Loop Diuretics Oral Contraceptives Stavudine GROUP
334,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",Thiamine,Loop Diuretics,int,Interactions Vitamin B1 ( DRUG ): GROUP Oral Contraceptives Stavudine Tricyclic Antidepressants
335,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",Thiamine,Contraceptives,int,Interactions Vitamin B1 ( DRUG ): Loop Diuretics Oral GROUP Stavudine Tricyclic Antidepressants
336,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",Thiamine,Stavudine,int,Interactions Vitamin B1 ( DRUG ): Loop Diuretics Oral Contraceptives DRUG Tricyclic Antidepressants
337,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",Thiamine,Tricyclic Antidepressants,int,Interactions Vitamin B1 ( DRUG ): Loop Diuretics Oral Contraceptives Stavudine GROUP
338,"Use with Anticholinergics: Because of their mechanism of action, cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications. ",cholinesterase inhibitors,anticholinergic medications,int,Use Anticholinergics: mechanism action GROUP potential interfere activity GROUP .
339,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",cholinesterase inhibitors,succinylcholine,effect,Use Cholinomimetics Cholinesterase Inhibitors: synergistic effect may expected GROUP given concurrently DRUG similar neuromuscular blocking agents cholinergic agonists bethanechol.
340,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",cholinesterase inhibitors,neuromuscular blocking agents,effect,Use Cholinomimetics Cholinesterase Inhibitors: synergistic effect may expected GROUP given concurrently succinylcholine similar GROUP cholinergic agonists bethanechol.
341,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",cholinesterase inhibitors,cholinergic agonists,effect,Use Cholinomimetics Cholinesterase Inhibitors: synergistic effect may expected GROUP given concurrently succinylcholine similar neuromuscular blocking agents GROUP bethanechol.
342,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",cholinesterase inhibitors,bethanechol,effect,Use Cholinomimetics Cholinesterase Inhibitors: synergistic effect may expected GROUP given concurrently succinylcholine similar neuromuscular blocking agents cholinergic agonists DRUG .
343,"Ketoconazole: Spontaneous adverse reaction reports of patients taking concomitant ketoconazole with recommended doses of terfenadine demonstrate QT interval prolongation and rare serious cardiac events, e.g. ",ketoconazole,terfenadine,effect,Ketoconazole: Spontaneous adverse reaction reports patients taking concomitant DRUG recommended doses DRUG demonstrate QT interval prolongation rare serious cardiac events e.g.
344,"Pharmacokinetic data indicate that ketoconazole markedly inhibits the metabolism of terfenadine, resulting in elevated plasma terfenadine levels. ",ketoconazole,terfenadine,mechanism,Pharmacokinetic data indicate DRUG markedly inhibits metabolism DRUG resulting elevated plasma terfenadine levels.
345,Concomitant administration of ketoconazole and terfenadine is contraindicated. ,ketoconazole,terfenadine,advise,Concomitant administration DRUG DRUG contraindicated.
346,Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. ,terfenadine,itraconazole,mechanism,Itraconazole: Torsades de pointes elevated parent terfenadine levels reported concomitant use DRUG DRUG clinical trials itraconazole foreign post marketing sources.
347,Concomitant administration of itraconazole and terfenadine is contraindicated. ,itraconazole,terfenadine,advise,Concomitant administration DRUG DRUG contraindicated.
348,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",azole-type antifungal agents,terfenadine,advise,Due chemical similarity GROUP (including fluconazole metronidazole miconazole) ketoconazole itraconazole concomitant use products DRUG recommended pending full examination potential interactions.
349,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",fluconazole,terfenadine,advise,Due chemical similarity azole type antifungal agents (including DRUG metronidazole miconazole) ketoconazole itraconazole concomitant use products DRUG recommended pending full examination potential interactions.
350,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",metronidazole,terfenadine,advise,Due chemical similarity azole type antifungal agents (including fluconazole DRUG miconazole) ketoconazole itraconazole concomitant use products DRUG recommended pending full examination potential interactions.
351,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",miconazole,terfenadine,advise,Due chemical similarity azole type antifungal agents (including fluconazole metronidazole DRUG ) ketoconazole itraconazole concomitant use products DRUG recommended pending full examination potential interactions.
352,"Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. ",erythromycin,terfenadine,mechanism,Macrolides: Clinical drug interaction studies indicate DRUG clarithromycin exert effect DRUG metabolism mechanism may similar ketoconazole lesser extent.
353,"Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. ",clarithromycin,terfenadine,mechanism,Macrolides: Clinical drug interaction studies indicate erythromycin DRUG exert effect DRUG metabolism mechanism may similar ketoconazole lesser extent.
354,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",terfenadine,clarithromycin,advise,Concomitant administration DRUG DRUG erythromycin troleandomycin contraindicated: Pending full characterization potential interactions concomitant administration terfenadine macrolide antibiotics including azithromycin recommended.
355,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",terfenadine,erythromycin,advise,Concomitant administration DRUG clarithromycin DRUG troleandomycin contraindicated: Pending full characterization potential interactions concomitant administration terfenadine macrolide antibiotics including azithromycin recommended.
356,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",terfenadine,troleandomycin,advise,Concomitant administration DRUG clarithromycin erythromycin DRUG contraindicated: Pending full characterization potential interactions concomitant administration terfenadine macrolide antibiotics including azithromycin recommended.
357,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",terfenadine,macrolide antibiotics,advise,Concomitant administration terfenadine clarithromycin erythromycin troleandomycin contraindicated: Pending full characterization potential interactions concomitant administration DRUG GROUP including azithromycin recommended.
358,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",terfenadine,azithromycin,advise,Concomitant administration terfenadine clarithromycin erythromycin troleandomycin contraindicated: Pending full characterization potential interactions concomitant administration DRUG macrolide antibiotics including DRUG recommended.
359,Caution is recommended when administering NEXAVAR with compounds that are metabolized/eliminated predominantly by the UGT1A1 pathway (e.g. irinotecan). ,NEXAVAR,irinotecan,advise,Caution recommended administering BRAND compounds metabolized/eliminated predominantly UGT1A1 pathway (e.g. DRUG ).
360,Concomitant treatment with NEXAVAR resulted in a 21% increase in the AUC of doxorubicin. ,NEXAVAR,doxorubicin,mechanism,Concomitant treatment BRAND resulted 21% increase AUC DRUG .
361,Caution is recommended when administering doxorubicin with NEXAVAR. ,doxorubicin,NEXAVAR,advise,Caution recommended administering DRUG BRAND .
362,"In a formal, single-dose interaction study (n = 6 males) the clearance of mexiletine was decreased by 38% following the coadministration of fluvoxamine, an inhibitor of CYP1A2. ",mexiletine,fluvoxamine,mechanism,formal single dose interaction study (n = 6 males) clearance DRUG decreased 38% following coadministration DRUG inhibitor CYP1A2.
363,"When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. ",phenytoin,Mexitil,mechanism,DRUG hepatic enzyme inducers rifampin phenobarbital taken concurrently BRAND lowered Mexitil plasma levels reported.
364,"When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. ",rifampin,Mexitil,mechanism,phenytoin hepatic enzyme inducers DRUG phenobarbital taken concurrently BRAND lowered Mexitil plasma levels reported.
365,"When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. ",phenobarbital,Mexitil,mechanism,phenytoin hepatic enzyme inducers rifampin DRUG taken concurrently BRAND lowered Mexitil plasma levels reported.
366,"Concurrent administration of cimetidine and Mexitil    has been reported to increase, decrease, or leave unchanged Mexitil    plasma levels; ",cimetidine,Mexitil,mechanism,Concurrent administration DRUG BRAND reported increase decrease leave unchanged Mexitil plasma levels;
367,"Mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels. ",magnesium-aluminum hydroxide,digoxin,mechanism,Mexitil alter serum digoxin levels DRUG used treat gastrointestinal symptoms due Mexitil reported lower serum DRUG levels.
368,Concurrent use of Mexitil    and theophylline may lead to increased plasma theophylline levels. ,Mexitil,theophylline,mechanism,Concurrent use BRAND DRUG may lead increased plasma theophylline levels.
369,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",Theophylline,Mexitil,mechanism,increase observed first test point second day starting Mexitil . DRUG plasma levels returned pre Mexitil values within 48 hours discontinuing BRAND . Mexitil theophylline used concurrently theophylline blood levels monitored particularly Mexitil dose changed.
370,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",Mexitil,theophylline,advise,increase observed first test point second day starting Mexitil . Theophylline plasma levels returned pre Mexitil values within 48 hours discontinuing Mexitil . BRAND DRUG used concurrently theophylline blood levels monitored particularly Mexitil dose changed.
371,"Additionally, in one controlled study in five normal subjects and seven patients, the clearance of caffeine was decreased 50% following the administration of Mexitil   .",caffeine,Mexitil,mechanism,Additionally one controlled study five normal subjects seven patients clearance DRUG decreased 50% following administration BRAND .
372,"Usage with Alcohol: Due to the potential for increased CNS depressants effects, alcohol should be used with caution in patients who are currently receiving pentazocine.",alcohol,pentazocine,advise,Usage Alcohol: Due potential increased CNS depressants effects DRUG used caution patients currently receiving DRUG .
373,Reduction of PTH by cinacalcet is associated with a decrease in darbepoetin requirement. ,cinacalcet,darbepoetin,effect,Reduction PTH DRUG associated decrease DRUG requirement.
374,"Thiabendazole may compete with other drugs, such as theophylline, for sites of metabolism in the liver, thus elevating the serum levels of such compounds to potentially toxic levels. ",Thiabendazole,theophylline,mechanism,DRUG may compete drugs DRUG sites metabolism liver thus elevating serum levels compounds potentially toxic levels.
375,"Therefore, when concomitant use of thiabendazole and xanthine derivatives is anticipated, it may be necessary to monitor blood levels and/or reduce the dosage of such compounds. ",thiabendazole,xanthine derivatives,advise,Therefore concomitant use DRUG GROUP anticipated may necessary monitor blood levels and/or reduce dosage compounds.
376,Mild hepatotoxicity has been reported in some patients when lorazepam and pyrimethamine were administered concomitantly.,lorazepam,pyrimethamine,effect,Mild hepatotoxicity reported patients DRUG DRUG administered concomitantly.
377,"Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ",Warfarin,citalopram,effect,DRUG users increased odds ratio gastrointestinal bleeding upon initiation DRUG (OR = 1.73 [95% CI 1.25 2.38]) fluoxetine (OR = 1.63 [95% CI 1.11 2.38]) paroxetine (OR = 1.64 [95% CI 1.27 2.12]) amitriptyline (OR = 1.47 [95% CI 1.02 2.11]).
378,"Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ",Warfarin,fluoxetine,effect,DRUG users increased odds ratio gastrointestinal bleeding upon initiation citalopram (OR = 1.73 [95% CI 1.25 2.38]) DRUG (OR = 1.63 [95% CI 1.11 2.38]) paroxetine (OR = 1.64 [95% CI 1.27 2.12]) amitriptyline (OR = 1.47 [95% CI 1.02 2.11]).
379,"Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ",Warfarin,paroxetine,effect,DRUG users increased odds ratio gastrointestinal bleeding upon initiation citalopram (OR = 1.73 [95% CI 1.25 2.38]) fluoxetine (OR = 1.63 [95% CI 1.11 2.38]) DRUG (OR = 1.64 [95% CI 1.27 2.12]) amitriptyline (OR = 1.47 [95% CI 1.02 2.11]).
380,"Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ",Warfarin,amitriptyline,effect,DRUG users increased odds ratio gastrointestinal bleeding upon initiation citalopram (OR = 1.73 [95% CI 1.25 2.38]) fluoxetine (OR = 1.63 [95% CI 1.11 2.38]) paroxetine (OR = 1.64 [95% CI 1.27 2.12]) DRUG (OR = 1.47 [95% CI 1.02 2.11]).
381,"Also mirtazapine, which is not believed to interact with warfarin, increased the risk of GI bleeding (OR   =   1.75 [95% CI, 1.30-2.35]). ",mirtazapine,warfarin,effect,Also DRUG believed interact DRUG increased risk GI bleeding (OR = 1.75 [95% CI 1.30 2.35]).
382,"Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",Warfarin,citalopram,effect,DRUG users initiated DRUG fluoxetine paroxetine amitriptyline mirtazapine increased risk hospitalization gastrointestinal bleeding.
383,"Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",Warfarin,fluoxetine,effect,DRUG users initiated citalopram DRUG paroxetine amitriptyline mirtazapine increased risk hospitalization gastrointestinal bleeding.
384,"Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",Warfarin,paroxetine,effect,DRUG users initiated citalopram fluoxetine DRUG amitriptyline mirtazapine increased risk hospitalization gastrointestinal bleeding.
385,"Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",Warfarin,amitriptyline,effect,DRUG users initiated citalopram fluoxetine paroxetine DRUG mirtazapine increased risk hospitalization gastrointestinal bleeding.
386,"Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",Warfarin,mirtazapine,effect,DRUG users initiated citalopram fluoxetine paroxetine amitriptyline DRUG increased risk hospitalization gastrointestinal bleeding.
387,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",Posicor,terfenadine,mechanism,BRAND inhibits liver's ability metabolize drugs DRUG astemizole cisapride cyclosporine tricyclic antidepressants.
388,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",Posicor,astemizole,mechanism,BRAND inhibits liver's ability metabolize drugs terfenadine DRUG cisapride cyclosporine tricyclic antidepressants.
389,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",Posicor,cisapride,mechanism,BRAND inhibits liver's ability metabolize drugs terfenadine astemizole DRUG cyclosporine tricyclic antidepressants.
390,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",Posicor,cyclosporine,mechanism,BRAND inhibits liver's ability metabolize drugs terfenadine astemizole cisapride DRUG tricyclic antidepressants.
391,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",Posicor,tricyclic antidepressants,mechanism,BRAND inhibits liver's ability metabolize drugs terfenadine astemizole cisapride cyclosporine GROUP .
392,"In experiment 2, the same regimen of GSLS was administered to chickens inoculated with inactivated AI vaccines, and an enhanced serum antibody response to AI vaccination was also observed. ",GSLS,inactivated AI vaccines,effect,experiment 2 regimen DRUG_N administered chickens inoculated DRUG enhanced serum antibody response AI vaccination also observed.
393,Trilostane may interact with aminoglutethimide or mitotane (causing too great a decrease in adrenal function).,Trilostane,aminoglutethimide,int,DRUG may interact DRUG mitotane (causing great decrease adrenal function).
394,Trilostane may interact with aminoglutethimide or mitotane (causing too great a decrease in adrenal function).,Trilostane,mitotane,int,DRUG may interact aminoglutethimide DRUG (causing great decrease adrenal function).
395,Calcium is the only known component in the diet that may affect absorption of both nonheme and heme iron. ,Calcium,nonheme iron,mechanism,DRUG known component diet may affect absorption nonheme heme DRUG .
396,Calcium is the only known component in the diet that may affect absorption of both nonheme and heme iron. ,Calcium,heme iron,mechanism,DRUG known component diet may affect absorption nonheme DRUG .
397,"However, the evidence for a calcium effect on iron absorption mainly comes from studies that did not isolate the effect of calcium from that of other dietary components, because it was detected in single-meal studies. ",calcium,iron,mechanism,However evidence DRUG effect DRUG absorption mainly comes studies isolate effect calcium dietary components detected single meal studies.
398,Calcium doses   1000 mg diminished nonheme iron absorption by an average of 49.6%.,Calcium,nonheme iron,mechanism,DRUG doses 1000 mg diminished DRUG absorption average 49.6%.
399,A calcium dose of 800 mg diminished absorption of 5 mg heme iron by 37.7%. ,calcium,heme iron,mechanism,DRUG dose 800 mg diminished absorption 5 mg DRUG 37.7%.
400,"In conclusion, we demonstrated an isolated effect of calcium (as chloride) on absorption of 5 mg of iron provided as nonheme (as sulfate) and heme (as CRBC) iron. ",calcium,nonheme iron,mechanism,conclusion demonstrated isolated effect DRUG (as chloride) absorption 5 mg iron provided nonheme (as sulfate) heme (as CRBC) DRUG .
401,"In conclusion, we demonstrated an isolated effect of calcium (as chloride) on absorption of 5 mg of iron provided as nonheme (as sulfate) and heme (as CRBC) iron. ",calcium,heme iron,mechanism,conclusion demonstrated isolated effect DRUG (as chloride) absorption 5 mg iron provided nonheme (as sulfate) heme (as CRBC) DRUG .
402,Ritalin may decrease the hypotensive effect of guanethidine. ,Ritalin,guanethidine,effect,BRAND may decrease hypotensive effect DRUG .
403,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,coumarin anticoagulants,mechanism,Human pharmacologic studies shown BRAND may inhibit metabolism GROUP anticonvulsants (phenobarbital diphenylhydantoin primidone) phenylbutazone tricyclic drugs (imipramine clomipramine desipramine).
404,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,anticonvulsants,mechanism,Human pharmacologic studies shown BRAND may inhibit metabolism coumarin anticoagulants GROUP (phenobarbital diphenylhydantoin primidone) phenylbutazone tricyclic drugs (imipramine clomipramine desipramine).
405,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,phenobarbital,mechanism,Human pharmacologic studies shown BRAND may inhibit metabolism coumarin anticoagulants anticonvulsants ( DRUG diphenylhydantoin primidone) phenylbutazone tricyclic drugs (imipramine clomipramine desipramine).
406,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,diphenylhydantoin,mechanism,Human pharmacologic studies shown BRAND may inhibit metabolism coumarin anticoagulants anticonvulsants (phenobarbital DRUG primidone) phenylbutazone tricyclic drugs (imipramine clomipramine desipramine).
407,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,primidone,mechanism,Human pharmacologic studies shown BRAND may inhibit metabolism coumarin anticoagulants anticonvulsants (phenobarbital diphenylhydantoin DRUG ) phenylbutazone tricyclic drugs (imipramine clomipramine desipramine).
408,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,phenylbutazone,mechanism,Human pharmacologic studies shown BRAND may inhibit metabolism coumarin anticoagulants anticonvulsants (phenobarbital diphenylhydantoin primidone) DRUG tricyclic drugs (imipramine clomipramine desipramine).
409,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,tricyclic drugs,mechanism,Human pharmacologic studies shown BRAND may inhibit metabolism coumarin anticoagulants anticonvulsants (phenobarbital diphenylhydantoin primidone) phenylbutazone GROUP (imipramine clomipramine desipramine).
410,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,imipramine,mechanism,Human pharmacologic studies shown BRAND may inhibit metabolism coumarin anticoagulants anticonvulsants (phenobarbital diphenylhydantoin primidone) phenylbutazone tricyclic drugs ( DRUG clomipramine desipramine).
411,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,clomipramine,mechanism,Human pharmacologic studies shown BRAND may inhibit metabolism coumarin anticoagulants anticonvulsants (phenobarbital diphenylhydantoin primidone) phenylbutazone tricyclic drugs (imipramine DRUG desipramine).
412,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,desipramine,mechanism,Human pharmacologic studies shown BRAND may inhibit metabolism coumarin anticoagulants anticonvulsants (phenobarbital diphenylhydantoin primidone) phenylbutazone tricyclic drugs (imipramine clomipramine DRUG ).
413,Increases of 5-FU plasma concentrations by approximately 20% have been observed with doses of 130 mg/m2 ELOXATIN dosed every 3 weeks. ,5-FU,ELOXATIN,mechanism,Increases DRUG plasma concentrations approximately 20% observed doses 130 mg/m2 BRAND dosed every 3 weeks.
414,Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ,XENICAL,cyclosporine,mechanism,Cyclosporine: Preliminary data XENICAL cyclosporine drug interaction study indicate reduction cyclosporine plasma levels BRAND coadministered DRUG .
415,Fat-soluble Vitamin Supplements and Analogues: A pharmacokinetic interaction study showed a 30% reduction in beta-carotene supplement absorption when concomitantly administered with XENICAL. ,beta-carotene,XENICAL,mechanism,Fat soluble Vitamin Supplements Analogues: pharmacokinetic interaction study showed 30% reduction DRUG supplement absorption concomitantly administered BRAND .
416,XENICAL inhibited absorption of a vitamin E acetate supplement by approximately 60%. ,XENICAL,vitamin E acetate,mechanism,BRAND inhibited absorption DRUG supplement approximately 60%.
417,"Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.",vitamin K,XENICAL,mechanism,Therefore GROUP absorption may decreased BRAND patients chronic stable doses warfarin prescribed XENICAL monitored closely changes coagulation parameters.
418,"Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.",warfarin,XENICAL,advise,Therefore vitamin K absorption may decreased XENICAL patients chronic stable doses DRUG prescribed BRAND monitored closely changes coagulation parameters.
419,Terbinafine decreases the clearance of caffeine by 19%. ,Terbinafine,caffeine,mechanism,DRUG decreases clearance DRUG 19%.
420,Terbinafine increases the clearance of cyclosporine by 15%. ,Terbinafine,cyclosporine,mechanism,DRUG increases clearance DRUG 15%.
421,"There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and warfarin, however, a causal relationship between LAMISIL    Tablets and these changes has not been established. ",terbinafine,warfarin,effect,spontaneous reports increase decrease prothrombin times patients concomitantly taking oral DRUG DRUG however causal relationship LAMISIL Tablets changes established.
422,"Terbinafine clearance is increased 100% by rifampin, a CyP450 enzyme inducer, and decreased 33% by cimetidine, a CyP450 enzyme inhibitor. ",Terbinafine,rifampin,mechanism,DRUG clearance increased 100% DRUG CyP450 enzyme inducer decreased 33% cimetidine CyP450 enzyme inhibitor.
423,"Terbinafine clearance is increased 100% by rifampin, a CyP450 enzyme inducer, and decreased 33% by cimetidine, a CyP450 enzyme inhibitor. ",Terbinafine,cimetidine,mechanism,DRUG clearance increased 100% rifampin CyP450 enzyme inducer decreased 33% DRUG CyP450 enzyme inhibitor.
424,ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. ,ASPIRIN,DISALCID,effect,BRAND SALICYLATE DRUGS ADDITIVE BRAND MAY INCREASE PLASMA CONCENTRATIONS SALICYLIC ACID TOXIC LEVELS.
425,ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. ,SALICYLATE DRUGS,DISALCID,effect,ASPIRIN GROUP ADDITIVE BRAND MAY INCREASE PLASMA CONCENTRATIONS SALICYLIC ACID TOXIC LEVELS.
426,Salicylates given concomitantly with anticoagulant drugs may predispose to systemic bleeding. ,Salicylates,anticoagulant drugs,effect,GROUP given concomitantly GROUP may predispose systemic bleeding.
427,Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. ,Salicylates,antidiabetic drugs,effect,GROUP may enhance hypoglycemic effect oral GROUP sulfonylurea class.
428,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",Salicylate,penicillin,mechanism,GROUP competes number drugs protein binding sites notably DRUG thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids.
429,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",Salicylate,thiopental,mechanism,GROUP competes number drugs protein binding sites notably penicillin DRUG thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids.
430,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",Salicylate,thyroxine,mechanism,GROUP competes number drugs protein binding sites notably penicillin thiopental DRUG triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids.
431,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",Salicylate,triiodothyronine,mechanism,GROUP competes number drugs protein binding sites notably penicillin thiopental thyroxine DRUG phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids.
432,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",Salicylate,phenytoin,mechanism,GROUP competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine DRUG sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids.
433,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",Salicylate,sulfinpyrazone,mechanism,GROUP competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin DRUG naproxen warfarin methotrexate possibly corticosteroids.
434,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",Salicylate,naproxen,mechanism,GROUP competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone DRUG warfarin methotrexate possibly corticosteroids.
435,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",Salicylate,warfarin,mechanism,GROUP competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen DRUG methotrexate possibly corticosteroids.
436,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",Salicylate,methotrexate,mechanism,GROUP competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin DRUG possibly corticosteroids.
437,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",Salicylate,corticosteroids,mechanism,GROUP competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly GROUP .
438,"Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents. ",reserpine,beta-blocking agents,effect,Catecholamine depleting drugs (e.g. DRUG ) may additive effect given GROUP .
439,Pindolol has been shown to increase serum thioridazine levels when both drugs are co-administered. ,Pindolol,thioridazine,mechanism,DRUG shown increase serum DRUG levels drugs co administered.
440,"Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). ",ketoconazole,mifepristone,mechanism,Although specific drug food interactions mifepristone studied basis drug metabolism CYP 3A4 possible DRUG itraconazole erythromycin grapefruit juice may inhibit metabolism (increasing serum levels DRUG ).
441,"Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). ",itraconazole,mifepristone,mechanism,Although specific drug food interactions mifepristone studied basis drug metabolism CYP 3A4 possible ketoconazole DRUG erythromycin grapefruit juice may inhibit metabolism (increasing serum levels DRUG ).
442,"Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). ",erythromycin,mifepristone,mechanism,Although specific drug food interactions mifepristone studied basis drug metabolism CYP 3A4 possible ketoconazole itraconazole DRUG grapefruit juice may inhibit metabolism (increasing serum levels DRUG ).
443,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",anticonvulsants,mifepristone,mechanism,John Wort certain GROUP (phenytoin phenobarbital carbamazepine) may induce DRUG metabolism (lowering serum levels mifepristone).
444,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",phenytoin,mifepristone,mechanism,John Wort certain anticonvulsants ( DRUG phenobarbital carbamazepine) may induce DRUG metabolism (lowering serum levels mifepristone).
445,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",phenobarbital,mifepristone,mechanism,John Wort certain anticonvulsants (phenytoin DRUG carbamazepine) may induce DRUG metabolism (lowering serum levels mifepristone).
446,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",carbamazepine,mifepristone,mechanism,John Wort certain anticonvulsants (phenytoin phenobarbital DRUG ) may induce DRUG metabolism (lowering serum levels mifepristone).
447,"In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. ",quinpirole,amphetamine,effect,female rats neonatal DRUG_N treatment enhanced DRUG locomotor sensitization compared quinpirole free controls sensitized amphetamine.
448,Caution should be exercised when administering ZADAXIN therapy in combination with other immunomodulating drugs. ,ZADAXIN,immunomodulating drugs,advise,Caution exercised administering BRAND therapy combination GROUP .
449,Caution should be observed in administering DEMSER to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis. ,DEMSER,phenothiazines,advise,Caution observed administering BRAND patients receiving GROUP haloperidol extrapyramidal effects drugs expected potentiated inhibition catecholamine synthesis.
450,Caution should be observed in administering DEMSER to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis. ,DEMSER,haloperidol,advise,Caution observed administering BRAND patients receiving phenothiazines DRUG extrapyramidal effects drugs expected potentiated inhibition catecholamine synthesis.
451,Concurrent use of DEMSER with alcohol or other CNS depressants can increase their sedative effects.,DEMSER,alcohol,effect,Concurrent use BRAND DRUG CNS depressants increase sedative effects.
452,Concurrent use of DEMSER with alcohol or other CNS depressants can increase their sedative effects.,DEMSER,CNS depressants,effect,Concurrent use BRAND alcohol DRUG increase sedative effects.
453,The metabolism of Metopirone is accelerated by phenytoin; ,Metopirone,phenytoin,mechanism,metabolism BRAND accelerated DRUG ;
454,Metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity.,Metopirone,acetaminophen,mechanism,BRAND inhibits glucuronidation DRUG could possibly potentiate acetaminophen toxicity.
455,Metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity.,Metopirone,acetaminophen,effect,BRAND inhibits glucuronidation acetaminophen could possibly potentiate DRUG toxicity.
456,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",Dopamine antagonists,Permax,advise,GROUP neuroleptics (phenothiazines butyrophenones thioxanthines ) metoclopramide ordinarily administered concurrently BRAND (a dopamine agonist);
457,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",neuroleptics,Permax,advise,Dopamine antagonists GROUP (phenothiazines butyrophenones thioxanthines ) metoclopramide ordinarily administered concurrently BRAND (a dopamine agonist);
458,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",phenothiazines,Permax,advise,Dopamine antagonists neuroleptics ( GROUP butyrophenones thioxanthines ) metoclopramide ordinarily administered concurrently BRAND (a dopamine agonist);
459,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",butyrophenones,Permax,advise,Dopamine antagonists neuroleptics (phenothiazines GROUP thioxanthines ) metoclopramide ordinarily administered concurrently BRAND (a dopamine agonist);
460,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",thioxanthines,Permax,advise,Dopamine antagonists neuroleptics (phenothiazines butyrophenones GROUP ) metoclopramide ordinarily administered concurrently BRAND (a dopamine agonist);
461,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",metoclopramide,Permax,advise,Dopamine antagonists neuroleptics (phenothiazines butyrophenones thioxanthines ) DRUG ordinarily administered concurrently BRAND (a dopamine agonist);
462,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",ketoconazole,paricalcitol,mechanism,multiple dose drug drug interaction study demonstrated DRUG approximately doubled DRUG AUC0 . Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole.
463,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,ketoconazole,advise,multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 . Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing DRUG DRUG strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole.
464,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,atazanavir,advise,multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 . Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing DRUG ketoconazole strong P450 3A inhibitors including DRUG clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole.
465,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,clarithromycin,advise,multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 . Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing DRUG ketoconazole strong P450 3A inhibitors including atazanavir DRUG indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole.
466,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,indinavir,advise,multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 . Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing DRUG ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin DRUG itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole.
467,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,itraconazole,advise,multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 . Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing DRUG ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir DRUG nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole.
468,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,nefazodone,advise,multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 . Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing DRUG ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole DRUG nelfinavir ritonavir saquinavir telithromycin voriconazole.
469,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,nelfinavir,advise,multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 . Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing DRUG ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone DRUG ritonavir saquinavir telithromycin voriconazole.
470,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,ritonavir,advise,multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 . Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing DRUG ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir DRUG saquinavir telithromycin voriconazole.
471,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,saquinavir,advise,multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 . Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing DRUG ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir DRUG telithromycin voriconazole.
472,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,telithromycin,advise,multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 . Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing DRUG ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir DRUG voriconazole.
473,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,voriconazole,advise,multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 . Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing DRUG ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin DRUG .
474,"Dose adjustment of Zemplar Capsules may be required, and iPTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor such as ketoconazole. ",Zemplar,ketoconazole,advise,Dose adjustment BRAND Capsules may required iPTH serum calcium concentrations closely monitored patient initiates discontinues therapy strong CYP3A4 inhibitor DRUG .
475,"Drugs that impair intestinal absorption of fat-soluble vitamins, such as cholestyramine, may interfere with the absorption of Zemplar Capsules.",fat-soluble vitamins,cholestyramine,mechanism,Drugs impair intestinal absorption GROUP DRUG may interfere absorption Zemplar Capsules.
476,"Drugs that impair intestinal absorption of fat-soluble vitamins, such as cholestyramine, may interfere with the absorption of Zemplar Capsules.",cholestyramine,Zemplar,mechanism,Drugs impair intestinal absorption fat soluble vitamins DRUG may interfere absorption BRAND Capsules.
477,The combination of minocycline and fosfomycin can be synergistic against MRSA. ,minocycline,fosfomycin,effect,combination DRUG DRUG synergistic MRSA.
478,"Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.",aspirin,methazolamide,advise,Caution advised patients receiving high dose BRAND DRUG concomitantly anorexia tachypnea lethargy coma death reported concomitant use high dose aspirin carbonic anhydrase inhibitors.
479,"Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.",aspirin,carbonic anhydrase inhibitors,effect,Caution advised patients receiving high dose aspirin methazolamide concomitantly anorexia tachypnea lethargy coma death reported concomitant use high dose BRAND GROUP .
480,"However, interactions may be expected and FLOMAX capsules should NOT be used in combination with other alpha-adrenergic blocking agents. ",FLOMAX,alpha-adrenergic blocking agents,advise,However interactions may expected BRAND capsules used combination GROUP .
481,"Therefore, FLOMAX capsules should be used with caution in combination with cimetidine, particularly at doses higher than 0.4 mg. ",FLOMAX,cimetidine,advise,Therefore BRAND capsules used caution combination DRUG particularly doses higher 0.4 mg.
482,"Therefore, caution should be exercised with concomitant administration of warfarin and FLOMAX capsules.        ",warfarin,FLOMAX,advise,Therefore caution exercised concomitant administration DRUG BRAND capsules.
483,Limited published data indicate that GH treatment increases cytochrome P450 (CP450) mediated antipyrine clearance in man. ,GH,antipyrine,mechanism,Limited published data indicate DRUG treatment increases cytochrome P450 (CP450) mediated DRUG clearance man.
484,"These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). ",GH,corticosteroids,mechanism,data suggest DRUG administration may alter clearance compounds known metabolized CP450 liver enzymes (e.g. GROUP sex steroids anticonvulsants cyclosporin).
485,"These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). ",GH,sex steroids,mechanism,data suggest DRUG administration may alter clearance compounds known metabolized CP450 liver enzymes (e.g. corticosteroids GROUP anticonvulsants cyclosporin).
486,"These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). ",GH,anticonvulsants,mechanism,data suggest DRUG administration may alter clearance compounds known metabolized CP450 liver enzymes (e.g. corticosteroids sex steroids GROUP cyclosporin).
487,"These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). ",GH,cyclosporin,mechanism,data suggest DRUG administration may alter clearance compounds known metabolized CP450 liver enzymes (e.g. corticosteroids sex steroids anticonvulsants DRUG ).
488,The CNS depressant effects of oxycodone hydrochloride may be additive with that of other CNS depressants..,oxycodone hydrochloride,CNS depressants,effect,CNS depressant effects DRUG may additive GROUP ..
489,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",morphine,CNS depressants,effect,Use Central Nervous System Depressants: depressant effects DRUG potentiated presence GROUP alcohol sedatives antihistaminics psychotropic drugs.
490,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",morphine,alcohol,effect,Use Central Nervous System Depressants: depressant effects DRUG potentiated presence CNS depressants DRUG sedatives antihistaminics psychotropic drugs.
491,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",morphine,sedatives,effect,Use Central Nervous System Depressants: depressant effects DRUG potentiated presence CNS depressants alcohol GROUP antihistaminics psychotropic drugs.
492,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",morphine,antihistaminics,effect,Use Central Nervous System Depressants: depressant effects DRUG potentiated presence CNS depressants alcohol sedatives GROUP psychotropic drugs.
493,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",morphine,psychotropic drugs,effect,Use Central Nervous System Depressants: depressant effects DRUG potentiated presence CNS depressants alcohol sedatives antihistaminics GROUP .
494,"Use of neuroleptics in conjunction with oral morphine may increase the risk of respiratory depression, hypotension and profound sedation or coma. ",neuroleptics,morphine,effect,Use GROUP conjunction oral DRUG may increase risk respiratory depression hypotension profound sedation coma.
495,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",Agonist/antagonist analgesics,opioid agonist analgesic,advise,Interaction Mixed Agonist/Antagonist Opioid Analgesics: GROUP (i.e. pentazocine nalbuphine butorphanol buprenorphine) administered patients received receiving course therapy proof GROUP .
496,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",pentazocine,opioid agonist analgesic,advise,Interaction Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e. DRUG nalbuphine butorphanol buprenorphine) administered patients received receiving course therapy proof GROUP .
497,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",nalbuphine,opioid agonist analgesic,advise,Interaction Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e. pentazocine DRUG butorphanol buprenorphine) administered patients received receiving course therapy proof GROUP .
498,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",butorphanol,opioid agonist analgesic,advise,Interaction Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e. pentazocine nalbuphine DRUG buprenorphine) administered patients received receiving course therapy proof GROUP .
499,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",buprenorphine,opioid agonist analgesic,advise,Interaction Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e. pentazocine nalbuphine butorphanol DRUG ) administered patients received receiving course therapy proof GROUP .
500,"Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",Myfortic,magnesium,mechanism,Antacids: Absorption single dose BRAND decreased administered 12 stable renal transplant patients also taking DRUG aluminum containing antacids (30 mL): mean Cmax AUC(0 t) values MPA 25% 37% lower respectively Myfortic administered alone fasting conditions.
501,"Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",Myfortic,aluminum,mechanism,Antacids: Absorption single dose BRAND decreased administered 12 stable renal transplant patients also taking magnesium DRUG containing antacids (30 mL): mean Cmax AUC(0 t) values MPA 25% 37% lower respectively Myfortic administered alone fasting conditions.
502,It is recommended that Myfortic and antacids not be administered simultaneously. ,Myfortic,antacids,advise,recommended DRUG GROUP administered simultaneously.
503,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",Myfortic,azathioprine,advise,Azathioprine/Mycophenolate Mofetil: Given azathioprine mycophenolate mofetil inhibit purine metabolism recommended BRAND administered concomitantly DRUG mycophenolate mofetil.
504,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",Myfortic,mycophenolate mofetil,advise,Azathioprine/Mycophenolate Mofetil: Given azathioprine mycophenolate mofetil inhibit purine metabolism recommended BRAND administered concomitantly azathioprine DRUG .
505,"Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of Myfortic. ",Myfortic,cholestyramine,advise,Therefore administer DRUG DRUG agents may interfere enterohepatic recirculation drugs may bind bile acids example bile acid sequestrates oral activated charcoal potential reduce efficacy Myfortic.
506,"Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of Myfortic. ",Myfortic,activated charcoal,advise,Therefore administer DRUG cholestyramine agents may interfere enterohepatic recirculation drugs may bind bile acids example bile acid sequestrates oral DRUG potential reduce efficacy Myfortic.
507,"However, in a drug-drug interaction study, mean levonorgesterol AUC was decreased by 15% when coadministered with mycophenolate mofetil. ",levonorgesterol,mycophenolate mofetil,mechanism,However drug drug interaction study mean DRUG AUC decreased 15% coadministered DRUG .
508,"Therefore, it is recommended that oral contraceptives are co- administered with Myfortic with caution and additional birth control methods be considered. ",contraceptives,Myfortic,advise,Therefore recommended oral GROUP co administered BRAND caution additional birth control methods considered.
509,"Live Vaccines: During treatment with Myfortic, the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective. ",Myfortic,live attenuated vaccines,advise,Live Vaccines: treatment DRUG use GROUP avoided patients advised vaccinations may less effective.
510,"Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ",coumarin-type anticoagulants,FELDENE,int,Although occurred vitro studies coumarin type anticoagulants interactions GROUP reported BRAND since marketing therefore physicians closely monitor patients change dosage requirements administering FELDENE patients coumarin type anticoagulants highly protein bound drugs.
511,"Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ",FELDENE,coumarin-type anticoagulants,advise,Although occurred vitro studies coumarin type anticoagulants interactions coumarin type anticoagulants reported FELDENE since marketing therefore physicians closely monitor patients change dosage requirements administering BRAND patients GROUP highly protein bound drugs.
512,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",FELDENE,aspirin,mechanism,Plasma levels piroxicam depressed approximately 80% normal values BRAND administered conjunction BRAND (3900 mg/day) concomitant administration antacids effect piroxicam plasma levels . Nonsteroidal anti inflammatory agents including FELDENE reported increase steady state plasma lithium levels.
513,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",Nonsteroidal anti-inflammatory agents,lithium,mechanism,Plasma levels piroxicam depressed approximately 80% normal values FELDENE administered conjunction aspirin (3900 mg/day) concomitant administration antacids effect piroxicam plasma levels . GROUP including FELDENE reported increase steady state plasma DRUG levels.
514,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",FELDENE,lithium,mechanism,Plasma levels piroxicam depressed approximately 80% normal values FELDENE administered conjunction aspirin (3900 mg/day) concomitant administration antacids effect piroxicam plasma levels . Nonsteroidal anti inflammatory agents including BRAND reported increase steady state plasma DRUG levels.
515,"It is recommended that plasma lithium levels be monitored when initiating, adjusting and discontinuing FELDENE.",lithium,FELDENE,advise,recommended plasma DRUG levels monitored initiating adjusting discontinuing BRAND .
516,"Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all. ",Vasopressors,halothane,effect,GROUP particularly metaraminol may cause serious cardiac arrhythmias DRUG anesthesia therefore used great caution all.
517,"Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all. ",metaraminol,halothane,effect,Vasopressors particularly DRUG may cause serious cardiac arrhythmias DRUG anesthesia therefore used great caution all.
518,MAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). ,sympathomimetic pressor amines,monoamine oxidase inhibitors,effect,MAO Inhibitors pressor effect GROUP markedly potentiated patients receiving GROUP (MAOI).
519,MAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). ,sympathomimetic pressor amines,MAOI,effect,MAO Inhibitors pressor effect GROUP markedly potentiated patients receiving monoamine oxidase inhibitors ( GROUP ).
520,The pressor response of adrenergic agents may also be potentiated by tricyclic antidepressants.,adrenergic agents,tricyclic antidepressants,effect,pressor response GROUP may also potentiated GROUP .
521,Acromegalic patients with diabetes mellitus being treated with insulin and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with SOMAVERT. ,insulin,SOMAVERT,advise,Acromegalic patients diabetes mellitus treated DRUG and/or oral hypoglycemic agents may require dose reductions therapeutic agents initiation therapy BRAND .
522,Acromegalic patients with diabetes mellitus being treated with insulin and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with SOMAVERT. ,hypoglycemic,SOMAVERT,advise,Acromegalic patients diabetes mellitus treated insulin and/or oral GROUP agents may require dose reductions therapeutic agents initiation therapy BRAND .
523,"In clinical studies, patients on opioids often needed higher serum pegvisomant concentrations to achieve appropriate IGF-I suppression compared with patients not receiving opioids. ",opioids,pegvisomant,mechanism,clinical studies patients GROUP often needed higher serum DRUG concentrations achieve appropriate IGF suppression compared patients receiving opioids.
524,"Digoxin: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days. ",digoxin,sitagliptin,mechanism,Digoxin: slight increase area curve (AUC 11%) mean peak drug concentration (Cmax 18%) DRUG co administration 100 mg DRUG 10 days.
525,Limited evidence suggests that ascorbic acid may influence the intensity and duration of action of bishydroxycoumarin.,ascorbic acid,bishydroxycoumarin,mechanism,Limited evidence suggests DRUG may influence intensity duration action DRUG .
526,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",Vindesine,Phenytoin,int,DRUG interact drugs following categories: Blood dyscrasia: cause unpredictable myelotoxicity Bone marrow depressants: cause predictable dose related myelotoxicity Radiation therapy: may cause marrow depression Neurotoxic medications: cause neurologic toxicity DRUG : increase seizure activity Live virus vaccines: may potentiate replication vaccine virus may increase side effects vaccination decrease patient's response vaccine Mitomycin C: may cause shortness breath bronchospasm Killed virus vaccines: may decrease patient's response vaccine
527,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",Vindesine,Live virus vaccines,int,DRUG interact drugs following categories: Blood dyscrasia: cause unpredictable myelotoxicity Bone marrow depressants: cause predictable dose related myelotoxicity Radiation therapy: may cause marrow depression Neurotoxic medications: cause neurologic toxicity Phenytoin: increase seizure activity GROUP : may potentiate replication vaccine virus may increase side effects vaccination decrease patient's response vaccine Mitomycin C: may cause shortness breath bronchospasm Killed virus vaccines: may decrease patient's response vaccine
528,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",Vindesine,Mitomycin-C,int,DRUG interact drugs following categories: Blood dyscrasia: cause unpredictable myelotoxicity Bone marrow depressants: cause predictable dose related myelotoxicity Radiation therapy: may cause marrow depression Neurotoxic medications: cause neurologic toxicity Phenytoin: increase seizure activity Live virus vaccines: may potentiate replication vaccine virus may increase side effects vaccination decrease patient's response vaccine DRUG : may cause shortness breath bronchospasm Killed virus vaccines: may decrease patient's response vaccine
529,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",Vindesine,Killed virus vaccines,int,DRUG interact drugs following categories: Blood dyscrasia: cause unpredictable myelotoxicity Bone marrow depressants: cause predictable dose related myelotoxicity Radiation therapy: may cause marrow depression Neurotoxic medications: cause neurologic toxicity Phenytoin: increase seizure activity Live virus vaccines: may potentiate replication vaccine virus may increase side effects vaccination decrease patient's response vaccine Mitomycin C: may cause shortness breath bronchospasm GROUP : may decrease patient's response vaccine
530,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",potassium-sparing diuretics,ACE inhibitors,effect,Use GROUP (spironolactone triamterene amiloride) potassium supplements concomitantly GROUP increase risk hyperkalemia.
531,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",spironolactone,ACE inhibitors,effect,Use potassium sparing diuretics ( DRUG triamterene amiloride) potassium supplements concomitantly GROUP increase risk hyperkalemia.
532,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",triamterene,ACE inhibitors,effect,Use potassium sparing diuretics (spironolactone DRUG amiloride) potassium supplements concomitantly GROUP increase risk hyperkalemia.
533,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",amiloride,ACE inhibitors,effect,Use potassium sparing diuretics (spironolactone triamterene DRUG ) potassium supplements concomitantly GROUP increase risk hyperkalemia.
534,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",potassium,ACE inhibitors,effect,Use potassium sparing diuretics (spironolactone triamterene amiloride) DRUG supplements concomitantly GROUP increase risk hyperkalemia.
535,Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. ,ACE inhibitors,lithium,effect,Lithium: Increased serum lithium levels symptoms lithium toxicity reported patients receiving GROUP therapy DRUG .
536,"If a diuretic is also used, the risk of lithium toxicity may be increased. ",diuretic,lithium,effect,GROUP also used risk DRUG toxicity may increased.
537,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",Melatonin,aspirin,int,DRUG may interact following drugs: BRAND NSAIDs (may lower melatonin levels) fluvoxamine (bioavailability oral melatonin increased coadministration) beta blockers (may decrease melatonin levels) fluoxetine (reports psychotic episodes coadministered) progestin (coadministration melatonin progestin inhibit ovarian function women) benzodiazepenes sedating drugs (may result additive sedation increased incidence adverse effects) corticosteroids (coadministration melatonin corticosteroids may interfere efficacy corticosteroids).
538,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",Melatonin,NSAIDs,int,DRUG may interact following drugs: aspirin GROUP (may lower melatonin levels) fluvoxamine (bioavailability oral melatonin increased coadministration) beta blockers (may decrease melatonin levels) fluoxetine (reports psychotic episodes coadministered) progestin (coadministration melatonin progestin inhibit ovarian function women) benzodiazepenes sedating drugs (may result additive sedation increased incidence adverse effects) corticosteroids (coadministration melatonin corticosteroids may interfere efficacy corticosteroids).
539,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",Melatonin,fluvoxamine,int,DRUG may interact following drugs: aspirin NSAIDs (may lower melatonin levels) DRUG (bioavailability oral melatonin increased coadministration) beta blockers (may decrease melatonin levels) fluoxetine (reports psychotic episodes coadministered) progestin (coadministration melatonin progestin inhibit ovarian function women) benzodiazepenes sedating drugs (may result additive sedation increased incidence adverse effects) corticosteroids (coadministration melatonin corticosteroids may interfere efficacy corticosteroids).
540,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",Melatonin,beta blockers,int,DRUG may interact following drugs: aspirin NSAIDs (may lower melatonin levels) fluvoxamine (bioavailability oral melatonin increased coadministration) GROUP (may decrease melatonin levels) fluoxetine (reports psychotic episodes coadministered) progestin (coadministration melatonin progestin inhibit ovarian function women) benzodiazepenes sedating drugs (may result additive sedation increased incidence adverse effects) corticosteroids (coadministration melatonin corticosteroids may interfere efficacy corticosteroids).
541,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",Melatonin,fluoxetine,int,DRUG may interact following drugs: aspirin NSAIDs (may lower melatonin levels) fluvoxamine (bioavailability oral melatonin increased coadministration) beta blockers (may decrease melatonin levels) DRUG (reports psychotic episodes coadministered) progestin (coadministration melatonin progestin inhibit ovarian function women) benzodiazepenes sedating drugs (may result additive sedation increased incidence adverse effects) corticosteroids (coadministration melatonin corticosteroids may interfere efficacy corticosteroids).
542,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",Melatonin,progestin,int,DRUG may interact following drugs: aspirin NSAIDs (may lower melatonin levels) fluvoxamine (bioavailability oral melatonin increased coadministration) beta blockers (may decrease melatonin levels) fluoxetine (reports psychotic episodes coadministered) GROUP (coadministration melatonin progestin inhibit ovarian function women) benzodiazepenes sedating drugs (may result additive sedation increased incidence adverse effects) corticosteroids (coadministration melatonin corticosteroids may interfere efficacy corticosteroids).
543,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",Melatonin,benzodiazepenes,int,DRUG may interact following drugs: aspirin NSAIDs (may lower melatonin levels) fluvoxamine (bioavailability oral melatonin increased coadministration) beta blockers (may decrease melatonin levels) fluoxetine (reports psychotic episodes coadministered) progestin (coadministration melatonin progestin inhibit ovarian function women) GROUP sedating drugs (may result additive sedation increased incidence adverse effects) corticosteroids (coadministration melatonin corticosteroids may interfere efficacy corticosteroids).
544,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",Melatonin,corticosteroids,int,DRUG may interact following drugs: aspirin NSAIDs (may lower melatonin levels) fluvoxamine (bioavailability oral melatonin increased coadministration) beta blockers (may decrease melatonin levels) fluoxetine (reports psychotic episodes coadministered) progestin (coadministration melatonin progestin inhibit ovarian function women) benzodiazepenes sedating drugs (may result additive sedation increased incidence adverse effects) GROUP (coadministration melatonin corticosteroids may interfere efficacy corticosteroids).
545,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,progestin,effect,Melatonin may interact following drugs: aspirin NSAIDs (may lower melatonin levels) fluvoxamine (bioavailability oral melatonin increased coadministration) beta blockers (may decrease melatonin levels) fluoxetine (reports psychotic episodes coadministered) progestin (coadministration DRUG GROUP inhibit ovarian function women) benzodiazepenes sedating drugs (may result additive sedation increased incidence adverse effects) corticosteroids (coadministration melatonin corticosteroids may interfere efficacy corticosteroids).
546,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,corticosteroids,effect,Melatonin may interact following drugs: aspirin NSAIDs (may lower melatonin levels) fluvoxamine (bioavailability oral melatonin increased coadministration) beta blockers (may decrease melatonin levels) fluoxetine (reports psychotic episodes coadministered) progestin (coadministration melatonin progestin inhibit ovarian function women) benzodiazepenes sedating drugs (may result additive sedation increased incidence adverse effects) corticosteroids (coadministration DRUG GROUP may interfere efficacy corticosteroids).
547,Alcohol: Concomitant administration of alcohol (equivalent to 60 g) had a minimal effect on plasma levels of mirtazapine (15 mg) in 6 healthy male subjects. ,alcohol,mirtazapine,mechanism,Alcohol: Concomitant administration DRUG (equivalent 60 g) minimal effect plasma levels DRUG (15 mg) 6 healthy male subjects.
548,"However, the impairment of cognitive and motor skills produced by REMERON    were shown to be additive with those produced by alcohol. ",REMERON,alcohol,effect,However impairment cognitive motor skills produced BRAND shown additive produced DRUG .
549,"Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. ",alcohol,REMERON SolTab,advise,Accordingly patients advised avoid DRUG taking BRAND . Diazepam: Concomitant administration diazepam (15 mg) minimal effect plasma levels mirtazapine (15 mg) 12 healthy subjects.
550,"Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. ",diazepam,mirtazapine,mechanism,Accordingly patients advised avoid alcohol taking REMERON SolTab. Diazepam: Concomitant administration DRUG (15 mg) minimal effect plasma levels DRUG (15 mg) 12 healthy subjects.
551,"However, the impairment of motor skills produced by REMERON has been shown to be additive with those caused by diazepam. ",REMERON,diazepam,effect,However impairment motor skills produced BRAND shown additive caused DRUG .
552,"Accordingly, patients should be advised to avoid diazepam and other similar drugs while taking REMERON SolTab.",diazepam,REMERON SolTab,advise,Accordingly patients advised avoid DRUG similar drugs taking BRAND .
553,Drug Interactions: Women on oral contraceptives have shown a significant increase in plasma vitamin A levels.,contraceptives,vitamin A,mechanism,Drug Interactions: Women oral GROUP shown significant increase plasma GROUP levels.
554,"Concomitant administration of CHEMET with other chelation therapy, such as CaNa 2 EDTA is not recommended. ",CHEMET,CaNa 2 EDTA,advise,Concomitant administration BRAND chelation therapy DRUG recommended.
555,AAV2-mediated retinal transduction is improved by co-injection of heparinase III or chondroitin ABC lyase. ,AAV2,heparinase III,effect,DRUG_N mediated retinal transduction improved co injection DRUG_N chondroitin ABC lyase.
556,AAV2-mediated retinal transduction is improved by co-injection of heparinase III or chondroitin ABC lyase. ,AAV2,chondroitin ABC lyase,effect,DRUG_N mediated retinal transduction improved co injection heparinase III DRUG_N .
557,"When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. ",methyldopa,antihypertensive drugs,effect,DRUG used GROUP potentiation antihypertensive effect may occur.
558,Patients may require reduced doses of anesthetics when on methyldopa. ,anesthetics,methyldopa,advise,Patients may require reduced doses GROUP DRUG .
559,When methyldopa and lithium are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity. ,methyldopa,lithium,advise,DRUG DRUG given concomitantly patient carefully monitored symptoms lithium toxicity.
560,Several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with ferrous sulfate or ferrous gluconate. ,methyldopa,ferrous sulfate,mechanism,Several studies demonstrate decrease bioavailability DRUG ingested DRUG ferrous gluconate.
561,Several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with ferrous sulfate or ferrous gluconate. ,methyldopa,ferrous gluconate,mechanism,Several studies demonstrate decrease bioavailability DRUG ingested ferrous sulfate DRUG .
562,Coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended. ,methyldopa,ferrous sulfate,advise,Coadministration DRUG DRUG ferrous gluconate recommended.
563,Coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended. ,methyldopa,ferrous gluconate,advise,Coadministration DRUG ferrous sulfate DRUG recommended.
564,norepinephrine and dobutamine are incompatible with sodium bicarbonate solution. ,norepinephrine,sodium bicarbonate,int,DRUG dobutamine incompatible DRUG solution.
565,norepinephrine and dobutamine are incompatible with sodium bicarbonate solution. ,dobutamine,sodium bicarbonate,int,norepinephrine DRUG incompatible DRUG solution.
566,"CRM197 induced apoptosis, and furthermore, the combination of CRM197 plus doxorubicin enhanced cytotoxicity in a T-ALL cell line. ",CRM197,doxorubicin,effect,CRM197 induced apoptosis furthermore combination DRUG_N plus DRUG enhanced cytotoxicity cell line.
567,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",SKELID,calcium,mechanism,bioavailability BRAND decreased 80% DRUG calcium SKELID administered time 60% aluminum magnesium containing antacids administered 1 hour SKELID.
568,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",aluminum,SKELID,mechanism,bioavailability SKELID decreased 80% calcium calcium SKELID administered time 60% DRUG magnesium containing antacids administered 1 hour BRAND .
569,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",magnesium,SKELID,mechanism,bioavailability SKELID decreased 80% calcium calcium SKELID administered time 60% aluminum DRUG containing antacids administered 1 hour BRAND .
570,Aspirin may decrease bioavailability of SKELID by up to 50% when taken 2 hours after SKELID. ,Aspirin,SKELID,mechanism,BRAND may decrease bioavailability BRAND 50% taken 2 hours SKELID.
571,The bioavailability of SKELID is increased 2-4 fold by indomethacin but is not significantly altered by coadministration of diclofenac. ,SKELID,indomethacin,mechanism,bioavailability BRAND increased 2 4 fold DRUG significantly altered coadministration diclofenac.
572,"Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.",Tetracycline,penicillin,effect,GROUP bacteriostatic antibiotic may antagonize bactericidal effect DRUG concurrent use drugs avoided.
573,"The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) ",DIPRIVAN,narcotics,effect,induction dose requirements BRAND Injectable Emulsion may reduced patients intramuscular intravenous premedication particularly GROUP (eg morphine meperidine fentanyl etc.)
574,"The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) ",DIPRIVAN,morphine,effect,induction dose requirements BRAND Injectable Emulsion may reduced patients intramuscular intravenous premedication particularly narcotics (eg DRUG meperidine fentanyl etc.)
575,"The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) ",DIPRIVAN,meperidine,effect,induction dose requirements BRAND Injectable Emulsion may reduced patients intramuscular intravenous premedication particularly narcotics (eg morphine DRUG fentanyl etc.)
576,"The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) ",DIPRIVAN,fentanyl,effect,induction dose requirements BRAND Injectable Emulsion may reduced patients intramuscular intravenous premedication particularly narcotics (eg morphine meperidine DRUG etc.)
577,"During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids). ",DIPRIVAN,analgesic agents,advise,maintenance anesthesia sedation rate BRAND Injectable Emulsion administration adjusted according desired level anesthesia sedation may reduced presence supplemental GROUP (eg nitrous oxide opioids).
578,"During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids). ",DIPRIVAN,nitrous oxide,advise,maintenance anesthesia sedation rate BRAND Injectable Emulsion administration adjusted according desired level anesthesia sedation may reduced presence supplemental analgesic agents (eg DRUG opioids).
579,"During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids). ",DIPRIVAN,opioids,advise,maintenance anesthesia sedation rate BRAND Injectable Emulsion administration adjusted according desired level anesthesia sedation may reduced presence supplemental analgesic agents (eg nitrous oxide GROUP ).
580,"Based on this experience, we suggest that low-dose ketamine added to propofol may be associated with prevention of EA in children with a history of EA with propofol TIVA.",ketamine,propofol,effect,Based experience suggest low dose DRUG added DRUG may associated prevention EA children history EA propofol TIVA.
581,"However, increased prothrombin time and bleeding have been reported in patients on concomitant TOLECTIN and warfarin therapy. ",TOLECTIN,warfarin,effect,However increased prothrombin time bleeding reported patients concomitant BRAND DRUG therapy.
582,"Therefore, caution should be exercised when administering TOLECTIN to patients on anticoagulants. ",TOLECTIN,anticoagulants,advise,Therefore caution exercised administering BRAND patients GROUP .
583,Caution should be used if TOLECTIN is administered concomitantly with methotrexate. ,TOLECTIN,methotrexate,advise,Caution used BRAND administered concomitantly DRUG .
584,"TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate. ",TOLECTIN,methotrexate,mechanism,BRAND nonsteroidal anti inflammatory drugs reported reduce tubular secretion DRUG animal model possibly enhancing toxicity methotrexate.
585,"TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate. ",nonsteroidal anti-inflammatory drugs,methotrexate,mechanism,TOLECTIN GROUP reported reduce tubular secretion DRUG animal model possibly enhancing toxicity methotrexate.
586,Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. ,Thiazide diuretics,phenothiazines,effect,GROUP may accentuate orthostatic hypotension may occur GROUP .
587,Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concomitantly. ,guanethidine,phenothiazines,effect,Antihypertensive effects DRUG related compounds may counteracted GROUP used concomitantly.
588,Concomitant administration of propranolol with phenothiazines results in increased plasma levels of both drugs.,propranolol,phenothiazines,mechanism,Concomitant administration DRUG GROUP results increased plasma levels drugs.
589,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",TOBI,dornase alfa,effect,clinical studies TOBI patients taking BRAND concomitantly DRUG (PULMOZYME Genentech) (beta) agonists inhaled corticosteroids anti pseudomonal antibiotics parenteral aminoglycosides demonstrated adverse experience profiles similar study population whole.
590,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",TOBI,PULMOZYME,effect,clinical studies TOBI patients taking BRAND concomitantly dornase alfa ( BRAND Genentech) (beta) agonists inhaled corticosteroids anti pseudomonal antibiotics parenteral aminoglycosides demonstrated adverse experience profiles similar study population whole.
591,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",TOBI,(beta)-agonists,effect,clinical studies TOBI patients taking BRAND concomitantly dornase alfa (PULMOZYME Genentech) GROUP inhaled corticosteroids anti pseudomonal antibiotics parenteral aminoglycosides demonstrated adverse experience profiles similar study population whole.
592,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",TOBI,corticosteroids,effect,clinical studies TOBI patients taking BRAND concomitantly dornase alfa (PULMOZYME Genentech) (beta) agonists inhaled GROUP anti pseudomonal antibiotics parenteral aminoglycosides demonstrated adverse experience profiles similar study population whole.
593,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",TOBI,anti-pseudomonal antibiotics,effect,clinical studies TOBI patients taking BRAND concomitantly dornase alfa (PULMOZYME Genentech) (beta) agonists inhaled corticosteroids GROUP parenteral aminoglycosides demonstrated adverse experience profiles similar study population whole.
594,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",TOBI,aminoglycosides,effect,clinical studies TOBI patients taking BRAND concomitantly dornase alfa (PULMOZYME Genentech) (beta) agonists inhaled corticosteroids anti pseudomonal antibiotics parenteral GROUP demonstrated adverse experience profiles similar study population whole.
595,Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. ,diuretics,aminoglycoside,effect,GROUP enhance GROUP toxicity altering antibiotic concentrations serum tissue.
596,"TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.",TOBI,ethacrynic acid,advise,BRAND administered concomitantly DRUG furosemide urea mannitol.
597,"TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.",TOBI,furosemide,advise,BRAND administered concomitantly ethacrynic acid DRUG urea mannitol.
598,"TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.",TOBI,urea,advise,BRAND administered concomitantly ethacrynic acid furosemide DRUG mannitol.
599,"TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.",TOBI,mannitol,advise,BRAND administered concomitantly ethacrynic acid furosemide urea DRUG .
600,An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of rosiglitazone. ,gemfibrozil,rosiglitazone,mechanism,inhibitor CYP2C8 (such DRUG ) may increase AUC DRUG inducer CYP2C8 (such rifampin) may decrease AUC rosiglitazone.
601,An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of rosiglitazone. ,rifampin,rosiglitazone,mechanism,inhibitor CYP2C8 (such gemfibrozil) may increase AUC rosiglitazone inducer CYP2C8 (such DRUG ) may decrease AUC DRUG .
602,Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA. ,Cholestyramine,raloxifene,mechanism,Cholestyramine: DRUG causes 60% reduction absorption enterohepatic cycling DRUG coadministered EVISTA.
603,Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA. ,Cholestyramine,EVISTA,advise,Cholestyramine: DRUG causes 60% reduction absorption enterohepatic cycling raloxifene coadministered BRAND .
604,"If EVISTA is given concurrently with warfarin, prothrombin time should be monitored. ",EVISTA,warfarin,advise,BRAND given concurrently DRUG prothrombin time monitored.
605,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",EVISTA,clofibrate,advise,Caution used BRAND coadministered highly protein bound drugs DRUG indomethacin naproxen ibuprofen diazepam diazoxide.
606,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",EVISTA,indomethacin,advise,Caution used BRAND coadministered highly protein bound drugs clofibrate DRUG naproxen ibuprofen diazepam diazoxide.
607,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",EVISTA,naproxen,advise,Caution used BRAND coadministered highly protein bound drugs clofibrate indomethacin DRUG ibuprofen diazepam diazoxide.
608,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",EVISTA,ibuprofen,advise,Caution used BRAND coadministered highly protein bound drugs clofibrate indomethacin naproxen DRUG diazepam diazoxide.
609,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",EVISTA,diazepam,advise,Caution used BRAND coadministered highly protein bound drugs clofibrate indomethacin naproxen ibuprofen DRUG diazoxide.
610,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",EVISTA,diazoxide,advise,Caution used BRAND coadministered highly protein bound drugs clofibrate indomethacin naproxen ibuprofen diazepam DRUG .
611,Other beta adrenergic aerosol bronchodilators should not be used concomitantly with Alupent    (metaproterenol sulfate USP) because they may have additive effects. ,beta adrenergic aerosol bronchodilators,Alupent,advise,GROUP used concomitantly BRAND (metaproterenol sulfate USP) may additive effects.
612,Other beta adrenergic aerosol bronchodilators should not be used concomitantly with Alupent    (metaproterenol sulfate USP) because they may have additive effects. ,beta adrenergic aerosol bronchodilators,metaproterenol sulfate,advise,GROUP used concomitantly Alupent ( DRUG USP) may additive effects.
613,"Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.",Beta adrenergic agonists,monoamine oxidase inhibitors,advise,GROUP administered caution patients treated GROUP tricyclic antidepressants since action beta adrenergic agonists vascular system may potentiated.
614,"Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.",Beta adrenergic agonists,tricyclic antidepressants,advise,GROUP administered caution patients treated monoamine oxidase inhibitors GROUP since action beta adrenergic agonists vascular system may potentiated.
615,"If ZEMURON    is administered following administration of succinylcholine, it should not be given until recovery from succinylcholine has been observed. ",ZEMURON,succinylcholine,advise,BRAND administered following administration DRUG given recovery succinylcholine observed.
616,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",phenytoin,ondansetron,mechanism,Phenytoin Carbamazepine Rifampicin: patients treated potent inducers CYP3A4 (i.e. DRUG carbamazepine rifampicin) clearance DRUG significantly increased ondansetron blood concentrations decreased.
617,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",phenytoin,ondansetron,mechanism,Phenytoin Carbamazepine Rifampicin: patients treated potent inducers CYP3A4 (i.e. DRUG carbamazepine rifampicin) clearance ondansetron significantly increased DRUG blood concentrations decreased.
618,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",carbamazepine,ondansetron,mechanism,Phenytoin Carbamazepine Rifampicin: patients treated potent inducers CYP3A4 (i.e. phenytoin DRUG rifampicin) clearance DRUG significantly increased ondansetron blood concentrations decreased.
619,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",carbamazepine,ondansetron,mechanism,Phenytoin Carbamazepine Rifampicin: patients treated potent inducers CYP3A4 (i.e. phenytoin DRUG rifampicin) clearance ondansetron significantly increased DRUG blood concentrations decreased.
620,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",rifampicin,ondansetron,mechanism,Phenytoin Carbamazepine Rifampicin: patients treated potent inducers CYP3A4 (i.e. phenytoin carbamazepine DRUG ) clearance DRUG significantly increased ondansetron blood concentrations decreased.
621,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",rifampicin,ondansetron,mechanism,Phenytoin Carbamazepine Rifampicin: patients treated potent inducers CYP3A4 (i.e. phenytoin carbamazepine DRUG ) clearance ondansetron significantly increased DRUG blood concentrations decreased.
622,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",ondansetron,tramadol,effect,However basis available data dosage adjustment ondansetron recommended patients drugs.1 3 Tramadol: Although pharmacokinetic drug interaction ondansetron tramadol observed data 2 small studies indicate DRUG may associated increase patient controlled administration DRUG .4 5 Chemotherapy: Tumor response chemotherapy P 388 mouse leukemia model affected ondansetron.
623,Administration of paclitaxel in combination with HERCEPTIN resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies.,paclitaxel,HERCEPTIN,mechanism,Administration DRUG combination BRAND resulted two fold decrease HERCEPTIN clearance non human primate study 1.5 fold increase HERCEPTIN serum levels clinical studies.
624,Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. ,macrolides,terfenadine,int,Concomitant administrations recommended: Terfenadine astemizole: Certain GROUP interact DRUG astemizole leading increased serum concentrations latter.
625,Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. ,macrolides,astemizole,int,Concomitant administrations recommended: Terfenadine astemizole: Certain GROUP interact terfenadine DRUG leading increased serum concentrations latter.
626,"Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended. ",roxithromycin,terfenadine,advise,Although reaction demonstrated roxithromycin concomitant administration DRUG DRUG astemizole recommended.
627,"Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended. ",roxithromycin,astemizole,advise,Although reaction demonstrated roxithromycin concomitant administration DRUG terfenadine DRUG recommended.
628,"- Cisapride, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. ",pimozide,macrolide antibacterials,mechanism,Cisapride DRUG : drugs cisapride pimozide metabolised hepatic CYP3A isozymes associated QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) result increase serum level subsequent interaction significant inhibitors isozyme including GROUP .
629,"- Cisapride, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. ",cisapride,macrolide antibacterials,mechanism,Cisapride pimozide: drugs DRUG pimozide metabolised hepatic CYP3A isozymes associated QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) result increase serum level subsequent interaction significant inhibitors isozyme including GROUP .
630,"Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",Streptase,antiplatelet agents,effect,Use Anticoagulants Antiplatelet Agents BRAND Streptokinase alone combination GROUP anticoagulants may cause bleeding complications.
631,"Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",Streptase,anticoagulants,effect,Use Anticoagulants Antiplatelet Agents BRAND Streptokinase alone combination antiplatelet agents GROUP may cause bleeding complications.
632,"Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",Streptokinase,antiplatelet agents,effect,Use Anticoagulants Antiplatelet Agents Streptase DRUG alone combination GROUP anticoagulants may cause bleeding complications.
633,"Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",Streptokinase,anticoagulants,effect,Use Anticoagulants Antiplatelet Agents Streptase DRUG alone combination antiplatelet agents GROUP may cause bleeding complications.
634,"The addition of aspirin to Streptokinase causes a minimal increase in the risk of minor bleeding (3.9% vs. 3.1%), but does not appear to increase the incidence of major bleeding (see",aspirin,Streptokinase,effect,addition BRAND DRUG causes minimal increase risk minor bleeding (3.9% vs. 3.1%) appear increase incidence major bleeding (see
635,MAO inhibitors and beta adrenergic blockers increase the effects of pseudoephedrine. ,MAO inhibitors,pseudoephedrine,effect,GROUP beta adrenergic blockers increase effects DRUG .
636,MAO inhibitors and beta adrenergic blockers increase the effects of pseudoephedrine. ,beta adrenergic blockers,pseudoephedrine,effect,MAO inhibitors GROUP increase effects DRUG .
637,"Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.",Sympathomimetics,methyldopa,effect,GROUP may reduce antihypertensive effects DRUG mecamylamine reserpine veratrum alkaloids.
638,"Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.",Sympathomimetics,mecamylamine,effect,GROUP may reduce antihypertensive effects methyldopa DRUG reserpine veratrum alkaloids.
639,"Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.",Sympathomimetics,reserpine,effect,GROUP may reduce antihypertensive effects methyldopa mecamylamine DRUG veratrum alkaloids.
640,"Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.",Sympathomimetics,veratrum alkaloids,effect,GROUP may reduce antihypertensive effects methyldopa mecamylamine reserpine GROUP .
641,Distinct and statistically significant synergism was observed between methylglyoxal and piperacillin by disc diffusion tests when compared with their individual effects. ,methylglyoxal,piperacillin,effect,Distinct statistically significant synergism observed DRUG_N DRUG disc diffusion tests compared individual effects.
642,Synergism was also noted when methylglyoxal was combined with carbenicillin and amikacin.,methylglyoxal,carbenicillin,effect,Synergism also noted DRUG_N combined DRUG amikacin.
643,Synergism was also noted when methylglyoxal was combined with carbenicillin and amikacin.,methylglyoxal,amikacin,effect,Synergism also noted DRUG_N combined carbenicillin DRUG .
644,"Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. ",tetracyclines,anticoagulant,advise,GROUP shown depress plasma prothrombin activity patients GROUP therapy may require downward adjustment anticoagulant dosage.
645,"Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline class drugs in conjunction with penicillin. ",tetracycline class drugs,penicillin,advise,Since bacteriostatic drugs may interfere bactericidal action penicillin advisable avoid giving GROUP conjunction DRUG .
646,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ",tetracyclines,aluminum,mechanism,Absorption GROUP impaired antacids containing DRUG calcium magnesium iron containing preparations.
647,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ",tetracyclines,calcium,mechanism,Absorption GROUP impaired antacids containing aluminum DRUG magnesium iron containing preparations.
648,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ",tetracyclines,magnesium,mechanism,Absorption GROUP impaired antacids containing aluminum calcium DRUG iron containing preparations.
649,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ",tetracyclines,iron,mechanism,Absorption GROUP impaired antacids containing aluminum calcium magnesium DRUG containing preparations.
650,The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity. ,tetracycline,methoxyflurane,effect,concurrent use GROUP DRUG reported result fatal renal toxicity.
651,Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.,tetracyclines,contraceptives,effect,Concurrent use GROUP oral GROUP may render oral contraceptives less effective.
652,"The concomitant use of Sanctura with other anticholinergic agents that produce dry mouth, constipation, and other anticholinergic pharmacological effects may increase the frequency and/or severity of such effects. ",Sanctura,anticholinergic agents,effect,concomitant use BRAND GROUP produce dry mouth constipation anticholinergic pharmacological effects may increase frequency and/or severity effects.
653,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",Sanctura,digoxin,mechanism,Drugs Eliminated Active Tubular Secretion: Although studies assess drug drug interactions Sanctura conducted BRAND potential pharmacokinetic interactions drugs eliminated active tubular secretion (e.g. DRUG procainamide pancuronium morphine vancomycin metformin tenofovir).
654,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",Sanctura,procainamide,mechanism,Drugs Eliminated Active Tubular Secretion: Although studies assess drug drug interactions Sanctura conducted BRAND potential pharmacokinetic interactions drugs eliminated active tubular secretion (e.g. digoxin DRUG pancuronium morphine vancomycin metformin tenofovir).
655,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",Sanctura,pancuronium,mechanism,Drugs Eliminated Active Tubular Secretion: Although studies assess drug drug interactions Sanctura conducted BRAND potential pharmacokinetic interactions drugs eliminated active tubular secretion (e.g. digoxin procainamide DRUG morphine vancomycin metformin tenofovir).
656,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",Sanctura,morphine,mechanism,Drugs Eliminated Active Tubular Secretion: Although studies assess drug drug interactions Sanctura conducted BRAND potential pharmacokinetic interactions drugs eliminated active tubular secretion (e.g. digoxin procainamide pancuronium DRUG vancomycin metformin tenofovir).
657,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",Sanctura,vancomycin,mechanism,Drugs Eliminated Active Tubular Secretion: Although studies assess drug drug interactions Sanctura conducted BRAND potential pharmacokinetic interactions drugs eliminated active tubular secretion (e.g. digoxin procainamide pancuronium morphine DRUG metformin tenofovir).
658,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",Sanctura,metformin,mechanism,Drugs Eliminated Active Tubular Secretion: Although studies assess drug drug interactions Sanctura conducted BRAND potential pharmacokinetic interactions drugs eliminated active tubular secretion (e.g. digoxin procainamide pancuronium morphine vancomycin DRUG tenofovir).
659,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",Sanctura,tenofovir,mechanism,Drugs Eliminated Active Tubular Secretion: Although studies assess drug drug interactions Sanctura conducted BRAND potential pharmacokinetic interactions drugs eliminated active tubular secretion (e.g. digoxin procainamide pancuronium morphine vancomycin metformin DRUG ).
660,DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.  ,Nalidixic acid,melphalan,effect,DRUG INTERACTIONS known drug/drug interactions oral ALKERAN Vaccinations live organism vaccines recommended immunocompromised individuals DRUG together high dose intravenous DRUG caused deaths children due haemorrhagic enterocolitis.
661,Impaired renal function has been described in bone marrow transplant patients who were conditioned with high-dose intravenous melphalan and who subsequently received cyclosporin to prevent graft-versus-host disease,melphalan,cyclosporin,effect,Impaired renal function described bone marrow transplant patients conditioned high dose intravenous DRUG subsequently received DRUG prevent graft versus host disease
662,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). ",midazolam,azole antimycotics,advise,Drug Interactions: Inhibitors CYP3A4 Isozymes: Caution advised DRUG administered concomitantly drugs known inhibit cytochrome P450 3A4 enzyme system (ie drugs drug classes GROUP protease inhibitors calcium channel antagonists macrolide antibiotics).
663,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). ",midazolam,protease inhibitors,advise,Drug Interactions: Inhibitors CYP3A4 Isozymes: Caution advised DRUG administered concomitantly drugs known inhibit cytochrome P450 3A4 enzyme system (ie drugs drug classes azole antimycotics GROUP calcium channel antagonists macrolide antibiotics).
664,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). ",midazolam,calcium channel antagonists,advise,Drug Interactions: Inhibitors CYP3A4 Isozymes: Caution advised DRUG administered concomitantly drugs known inhibit cytochrome P450 3A4 enzyme system (ie drugs drug classes azole antimycotics protease inhibitors GROUP macrolide antibiotics).
665,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). ",midazolam,macrolide antibiotics,advise,Drug Interactions: Inhibitors CYP3A4 Isozymes: Caution advised DRUG administered concomitantly drugs known inhibit cytochrome P450 3A4 enzyme system (ie drugs drug classes azole antimycotics protease inhibitors calcium channel antagonists GROUP ).
666,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",erythromycin,midazolam,mechanism,Drugs DRUG diltiazem verapamil ketoconazole fluconazole itraconazole shown significantly increase C max AUC orally administered DRUG .
667,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",diltiazem,midazolam,mechanism,Drugs erythromycin DRUG verapamil ketoconazole fluconazole itraconazole shown significantly increase C max AUC orally administered DRUG .
668,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",verapamil,midazolam,mechanism,Drugs erythromycin diltiazem DRUG ketoconazole fluconazole itraconazole shown significantly increase C max AUC orally administered DRUG .
669,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",ketoconazole,midazolam,mechanism,Drugs erythromycin diltiazem verapamil DRUG fluconazole itraconazole shown significantly increase C max AUC orally administered DRUG .
670,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",fluconazole,midazolam,mechanism,Drugs erythromycin diltiazem verapamil ketoconazole DRUG itraconazole shown significantly increase C max AUC orally administered DRUG .
671,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",itraconazole,midazolam,mechanism,Drugs erythromycin diltiazem verapamil ketoconazole fluconazole DRUG shown significantly increase C max AUC orally administered DRUG .
672,"Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam. ",ritonavir,midazolam,mechanism,Although studied potent cytochrome P450 3A4 inhibitors DRUG nelfinavir may cause intense prolonged sedation respiratory depression due decrease plasma clearance DRUG .
673,"Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam. ",nelfinavir,midazolam,mechanism,Although studied potent cytochrome P450 3A4 inhibitors ritonavir DRUG may cause intense prolonged sedation respiratory depression due decrease plasma clearance DRUG .
674,"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. ",rifampin,midazolam,mechanism,Inducers CYP3A4 Isozymes: Cytochrome P450 inducers DRUG carbamazepine phenytoin induce metabolism caused markedly decreased C max AUC oral DRUG adult studies.
675,"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. ",carbamazepine,midazolam,mechanism,Inducers CYP3A4 Isozymes: Cytochrome P450 inducers rifampin DRUG phenytoin induce metabolism caused markedly decreased C max AUC oral DRUG adult studies.
676,"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. ",phenytoin,midazolam,mechanism,Inducers CYP3A4 Isozymes: Cytochrome P450 inducers rifampin carbamazepine DRUG induce metabolism caused markedly decreased C max AUC oral DRUG adult studies.
677,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",VERSED Syrup,narcotics,effect,sedative effect BRAND accentuated concomitantly administered medication depresses central nervous system particularly GROUP (eg morphine meperidine fentanyl) propofol ketamine nitrous oxide secobarbital droperidol.
678,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",VERSED Syrup,morphine,effect,sedative effect BRAND accentuated concomitantly administered medication depresses central nervous system particularly narcotics (eg DRUG meperidine fentanyl) propofol ketamine nitrous oxide secobarbital droperidol.
679,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",VERSED Syrup,meperidine,effect,sedative effect BRAND accentuated concomitantly administered medication depresses central nervous system particularly narcotics (eg morphine DRUG fentanyl) propofol ketamine nitrous oxide secobarbital droperidol.
680,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",VERSED Syrup,fentanyl,effect,sedative effect BRAND accentuated concomitantly administered medication depresses central nervous system particularly narcotics (eg morphine meperidine DRUG ) propofol ketamine nitrous oxide secobarbital droperidol.
681,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",VERSED Syrup,propofol,effect,sedative effect BRAND accentuated concomitantly administered medication depresses central nervous system particularly narcotics (eg morphine meperidine fentanyl) DRUG ketamine nitrous oxide secobarbital droperidol.
682,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",VERSED Syrup,ketamine,effect,sedative effect BRAND accentuated concomitantly administered medication depresses central nervous system particularly narcotics (eg morphine meperidine fentanyl) propofol DRUG nitrous oxide secobarbital droperidol.
683,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",VERSED Syrup,nitrous oxide,effect,sedative effect BRAND accentuated concomitantly administered medication depresses central nervous system particularly narcotics (eg morphine meperidine fentanyl) propofol ketamine DRUG secobarbital droperidol.
684,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",VERSED Syrup,secobarbital,effect,sedative effect BRAND accentuated concomitantly administered medication depresses central nervous system particularly narcotics (eg morphine meperidine fentanyl) propofol ketamine nitrous oxide DRUG droperidol.
685,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",VERSED Syrup,droperidol,effect,sedative effect BRAND accentuated concomitantly administered medication depresses central nervous system particularly narcotics (eg morphine meperidine fentanyl) propofol ketamine nitrous oxide secobarbital DRUG .
686,"Drugs which may potentiate the myeloproliferative effects of Leukine, such as lithium and corticosteroids, should be used with caution.",Leukine,lithium,effect,Drugs may potentiate myeloproliferative effects BRAND DRUG corticosteroids used caution.
687,"Drugs which may potentiate the myeloproliferative effects of Leukine, such as lithium and corticosteroids, should be used with caution.",Leukine,corticosteroids,effect,Drugs may potentiate myeloproliferative effects BRAND lithium GROUP used caution.
688,"Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with TRENTAL with and without anticoagulants or platelet aggregation inhibitors. ",TRENTAL,anticoagulants,effect,Although causal relationship established reports bleeding and/or prolonged prothrombin time patients treated BRAND without GROUP platelet aggregation inhibitors.
689,"Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with TRENTAL with and without anticoagulants or platelet aggregation inhibitors. ",TRENTAL,platelet aggregation inhibitors,effect,Although causal relationship established reports bleeding and/or prolonged prothrombin time patients treated BRAND without anticoagulants GROUP .
690,Concomitant administration of TRENTAL and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. ,TRENTAL,theophylline,mechanism,Concomitant administration BRAND DRUG containing drugs leads increased theophylline levels theophylline toxicity individuals.
691,ACE inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of angiotensin-converting enzyme (ACE) inhibitors. ,NSAIDs,angiotensin-converting enzyme (ACE) inhibitors,effect,ACE inhibitors Reports suggest GROUP may diminish antihypertensive effect GROUP .
692,This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors. ,NSAIDs,ACE inhibitors,advise,interaction given consideration patients taking GROUP concomitantly GROUP .
693,Aspirin: Concomitant administration of aspirin (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of meloxicam. ,aspirin,meloxicam,mechanism,Aspirin: Concomitant administration BRAND (1000 mg TID) healthy volunteers tended increase AUC (10%) Cmax (24%) DRUG .
694,"however, as with other NSAIDs, concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects. ",NSAIDs,aspirin,advise,however GROUP concomitant administration meloxicam BRAND generally recommended potential increased adverse effects.
695,"however, as with other NSAIDs, concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects. ",meloxicam,aspirin,advise,however NSAIDs concomitant administration DRUG BRAND generally recommended potential increased adverse effects.
696,"Concomitant administration of low-dose aspirin with MOBIC may result in an increased rate of GI ulceration or other complications, compared to use of MOBIC alone. ",aspirin,MOBIC,effect,Concomitant administration low dose BRAND BRAND may result increased rate GI ulceration complications compared use MOBIC alone.
697,Cholestyramine: Pretreatment for four days with cholestyramine significantly increased the clearance of meloxicam by 50%. ,cholestyramine,meloxicam,mechanism,Cholestyramine: Pretreatment four days DRUG significantly increased clearance DRUG 50%.
698,"Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients. ",NSAIDs,furosemide,effect,Furosemide: Clinical studies well post marketing observations shown GROUP reduce natriuretic effect DRUG thiazide diuretics patients.
699,"Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients. ",NSAIDs,thiazide diuretics,effect,Furosemide: Clinical studies well post marketing observations shown GROUP reduce natriuretic effect furosemide GROUP patients.
700,"Nevertheless, during concomitant therapy with furosemide and MOBIC, patients should be observed closely for signs of declining renal function, as well as to assure diuretic efficacy. ",furosemide,MOBIC,advise,Nevertheless concomitant therapy DRUG BRAND patients observed closely signs declining renal function well assure diuretic efficacy.
701,"Lithium: In clinical trials, NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. ",NSAIDs,lithium,mechanism,Lithium: clinical trials GROUP produced elevation plasma DRUG levels reduction renal lithium clearance.
702,"In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone. ",lithium,meloxicam,mechanism,study conducted healthy subjects mean pre dose lithium concentration AUC increased 21% subjects receiving DRUG doses ranging 804 1072 mg BID DRUG 15 mg QD compared subjects receiving lithium alone.
703,Patients on lithium treatment should be closely monitored when MOBIC is introduced or withdrawn. ,lithium,MOBIC,advise,Patients DRUG treatment closely monitored BRAND introduced withdrawn.
704,"Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing MOBIC therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding. ",MOBIC,warfarin,advise,Warfarin: Anticoagulant activity monitored particularly first days initiating changing BRAND therapy patients receiving DRUG similar agents since patients increased risk bleeding.
705,Caution should be used when administering MOBIC with warfarin since patients on warfarin may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.,MOBIC,warfarin,advise,Caution used administering BRAND DRUG since patients warfarin may experience changes INR increased risk bleeding complications new medication introduced.
706,"When administered concomitantly with ProAmatine   , cardiac glycosides may enhance or precipitate bradycardia, A.V. ",ProAmatine,cardiac glycosides,effect,administered concomitantly BRAND GROUP may enhance precipitate bradycardia A.V.
707,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",phenylephrine,ProAmatine,effect,use drugs stimulate alpha adrenergic receptors (e.g. DRUG pseudoephedrine ephedrine phenylpropanolamine dihydroergotamine) may enhance potentiate pressor effects BRAND . Therefore caution used ProAmatine administered concomitantly agents cause vasoconstriction.
708,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",pseudoephedrine,ProAmatine,effect,use drugs stimulate alpha adrenergic receptors (e.g. phenylephrine DRUG ephedrine phenylpropanolamine dihydroergotamine) may enhance potentiate pressor effects BRAND . Therefore caution used ProAmatine administered concomitantly agents cause vasoconstriction.
709,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",ephedrine,ProAmatine,effect,use drugs stimulate alpha adrenergic receptors (e.g. phenylephrine pseudoephedrine DRUG phenylpropanolamine dihydroergotamine) may enhance potentiate pressor effects BRAND . Therefore caution used ProAmatine administered concomitantly agents cause vasoconstriction.
710,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",phenylpropanolamine,ProAmatine,effect,use drugs stimulate alpha adrenergic receptors (e.g. phenylephrine pseudoephedrine ephedrine DRUG dihydroergotamine) may enhance potentiate pressor effects BRAND . Therefore caution used ProAmatine administered concomitantly agents cause vasoconstriction.
711,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",dihydroergotamine,ProAmatine,effect,use drugs stimulate alpha adrenergic receptors (e.g. phenylephrine pseudoephedrine ephedrine phenylpropanolamine DRUG ) may enhance potentiate pressor effects BRAND . Therefore caution used ProAmatine administered concomitantly agents cause vasoconstriction.
712,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",Alpha-adrenergic blocking agents,ProAmatine,effect,ProAmatine. GROUP prazosin terazosin doxazosin antagonize effects BRAND . Potential Drug Interactions: appears possible although supporting experimental evidence high renal clearance desglymidodrine (a base) due active tubular secretion base secreting system also responsible secretion drugs metformin cimetidine ranitidine procainamide triamterene flecainide quinidine.
713,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",prazosin,ProAmatine,effect,ProAmatine. Alpha adrenergic blocking agents DRUG terazosin doxazosin antagonize effects BRAND . Potential Drug Interactions: appears possible although supporting experimental evidence high renal clearance desglymidodrine (a base) due active tubular secretion base secreting system also responsible secretion drugs metformin cimetidine ranitidine procainamide triamterene flecainide quinidine.
714,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",terazosin,ProAmatine,effect,ProAmatine. Alpha adrenergic blocking agents prazosin DRUG doxazosin antagonize effects BRAND . Potential Drug Interactions: appears possible although supporting experimental evidence high renal clearance desglymidodrine (a base) due active tubular secretion base secreting system also responsible secretion drugs metformin cimetidine ranitidine procainamide triamterene flecainide quinidine.
715,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",doxazosin,ProAmatine,effect,ProAmatine. Alpha adrenergic blocking agents prazosin terazosin DRUG antagonize effects BRAND . Potential Drug Interactions: appears possible although supporting experimental evidence high renal clearance desglymidodrine (a base) due active tubular secretion base secreting system also responsible secretion drugs metformin cimetidine ranitidine procainamide triamterene flecainide quinidine.
716,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",desglymidodrine,metformin,mechanism,ProAmatine. Alpha adrenergic blocking agents prazosin terazosin doxazosin antagonize effects ProAmatine. Potential Drug Interactions: appears possible although supporting experimental evidence high renal clearance DRUG_N (a base) due active tubular secretion base secreting system also responsible secretion drugs DRUG cimetidine ranitidine procainamide triamterene flecainide quinidine.
717,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",desglymidodrine,cimetidine,mechanism,ProAmatine. Alpha adrenergic blocking agents prazosin terazosin doxazosin antagonize effects ProAmatine. Potential Drug Interactions: appears possible although supporting experimental evidence high renal clearance DRUG_N (a base) due active tubular secretion base secreting system also responsible secretion drugs metformin DRUG ranitidine procainamide triamterene flecainide quinidine.
718,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",desglymidodrine,ranitidine,mechanism,ProAmatine. Alpha adrenergic blocking agents prazosin terazosin doxazosin antagonize effects ProAmatine. Potential Drug Interactions: appears possible although supporting experimental evidence high renal clearance DRUG_N (a base) due active tubular secretion base secreting system also responsible secretion drugs metformin cimetidine DRUG procainamide triamterene flecainide quinidine.
719,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",desglymidodrine,procainamide,mechanism,ProAmatine. Alpha adrenergic blocking agents prazosin terazosin doxazosin antagonize effects ProAmatine. Potential Drug Interactions: appears possible although supporting experimental evidence high renal clearance DRUG_N (a base) due active tubular secretion base secreting system also responsible secretion drugs metformin cimetidine ranitidine DRUG triamterene flecainide quinidine.
720,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",desglymidodrine,triamterene,mechanism,ProAmatine. Alpha adrenergic blocking agents prazosin terazosin doxazosin antagonize effects ProAmatine. Potential Drug Interactions: appears possible although supporting experimental evidence high renal clearance DRUG_N (a base) due active tubular secretion base secreting system also responsible secretion drugs metformin cimetidine ranitidine procainamide DRUG flecainide quinidine.
721,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",desglymidodrine,flecainide,mechanism,ProAmatine. Alpha adrenergic blocking agents prazosin terazosin doxazosin antagonize effects ProAmatine. Potential Drug Interactions: appears possible although supporting experimental evidence high renal clearance DRUG_N (a base) due active tubular secretion base secreting system also responsible secretion drugs metformin cimetidine ranitidine procainamide triamterene DRUG quinidine.
722,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",desglymidodrine,quinidine,mechanism,ProAmatine. Alpha adrenergic blocking agents prazosin terazosin doxazosin antagonize effects ProAmatine. Potential Drug Interactions: appears possible although supporting experimental evidence high renal clearance DRUG_N (a base) due active tubular secretion base secreting system also responsible secretion drugs metformin cimetidine ranitidine procainamide triamterene flecainide DRUG .
723,Preliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole.,cimetidine,mebendazole,mechanism,Preliminary evidence suggests DRUG inhibits DRUG metabolism may result increase plasma concentrations mebendazole.
724,Interactions for Vitamin B2 (Riboflavin):  Alcohol - impairs the intestinal absorption of riboflavin,Alcohol,riboflavin,mechanism,Interactions Vitamin B2 (Riboflavin): DRUG impairs intestinal absorption DRUG
725,Probenecid - concurrent use decreases gastrointestinal absorption of riboflavin; ,Probenecid,riboflavin,mechanism,DRUG concurrent use decreases gastrointestinal absorption DRUG ;
726,requirements for riboflavin may be increased in patients receiving probenecid.,riboflavin,probenecid,effect,requirements DRUG may increased patients receiving DRUG .
727,"Anticholinergics or other medications with anticholinergic activity when used concurrently with opioid analgesics may result in increased risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. ",Anticholinergics,opioid analgesics,effect,GROUP medications anticholinergic activity used concurrently GROUP may result increased risk urinary retention and/or severe constipation may lead paralytic ileus.
728,It has been reported that the incidence of bradycardia was increased when oxymorphone was combined with propofol for induction of anesthesia. ,oxymorphone,propofol,effect,reported incidence bradycardia increased DRUG combined DRUG induction anesthesia.
729,"In addition, CNS toxicity has been reported (confusion, disorientation, respiratory depression, apnea, seizures) following coadministration of cimetidine with opioid analgesics; ",cimetidine,opioid analgesics,effect,addition CNS toxicity reported (confusion disorientation respiratory depression apnea seizures) following coadministration DRUG GROUP ;
730,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",Celontin,antiepileptic drugs,advise,Since BRAND (methsuximide) may interact concurrently administered GROUP periodic serum level determinations drugs may necessary (eg methsuximide may increase plasma concentrations phenytoin phenobarbital).
731,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",methsuximide,antiepileptic drugs,advise,Since Celontin ( DRUG ) may interact concurrently administered GROUP periodic serum level determinations drugs may necessary (eg methsuximide may increase plasma concentrations phenytoin phenobarbital).
732,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",methsuximide,phenytoin,mechanism,Since Celontin (methsuximide) may interact concurrently administered antiepileptic drugs periodic serum level determinations drugs may necessary (eg DRUG may increase plasma concentrations DRUG phenobarbital).
733,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",methsuximide,phenobarbital,mechanism,Since Celontin (methsuximide) may interact concurrently administered antiepileptic drugs periodic serum level determinations drugs may necessary (eg DRUG may increase plasma concentrations phenytoin DRUG ).
734,"When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone. ",atropine,pralidoxime,effect,DRUG DRUG used together signs atropinization (flushing mydriasis tachycardia dryness mouth nose) may occur earlier might expected atropine used alone.
735,"2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of pralidoxime: since barbiturates are potentiated by the anticholinesterases, they should be used cautiously in the treatment of convulsions; ",barbiturates,anticholinesterases,effect,2 4 following precautions kept mind treatment anticholinesterase poisoning although bear directly use pralidoxime: since GROUP potentiated GROUP used cautiously treatment convulsions;
736,Anticoagulants Anabolic steroids may increase sensitivity to oral anticoagulants. ,Anabolic steroids,anticoagulants,effect,Anticoagulants GROUP may increase sensitivity oral GROUP .
737,"Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. ",oxandrolone,warfarin,mechanism,Warfarin: multidose study DRUG given 5 10 mg BID 15 healthy subjects concurrently treated DRUG resulted mean increase warfarin half life 26 48 hours AUC 4.55 12.08 ng*hr/mL: similar increases R warfarin half life AUC also detected.
738,"When oxandrolone therapy is initiated in a patient already receiving treatment with warfarin, the INR or prothrombin time (PT) should be monitored closely and the dose of warfarin adjusted as necessary until a stable target INR or PT has been achieved. ",oxandrolone,warfarin,advise,DRUG therapy initiated patient already receiving treatment DRUG INR prothrombin time (PT) monitored closely dose warfarin adjusted necessary stable target INR PT achieved.
739,"Furthermore, in patients receiving both drugs, careful monitoring of the INR or PT, and adjustment of the warfarin dosage if indicated are recommended when the oxandrolone dose is changed or discontinued. ",warfarin,oxandrolone,advise,Furthermore patients receiving drugs careful monitoring INR PT adjustment DRUG dosage indicated recommended DRUG dose changed discontinued.
740,Oral hypoglycemic agents Oxandrolone may inhibit the metabolism of oral hypoglycemic agents. ,Oxandrolone,hypoglycemic agents,mechanism,Oral hypoglycemic agents DRUG may inhibit metabolism oral GROUP .
741,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,Moxifloxacin,sucralfate,mechanism,DRUG Lomefloxacin reacts faster DRUG gelusil acidic media whereas erythromycin basic media multi minerals neutral media.
742,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,Moxifloxacin,gelusil,mechanism,DRUG Lomefloxacin reacts faster sucralfate BRAND acidic media whereas erythromycin basic media multi minerals neutral media.
743,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,Moxifloxacin,erythromycin,mechanism,DRUG Lomefloxacin reacts faster sucralfate gelusil acidic media whereas DRUG basic media multi minerals neutral media.
744,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,Moxifloxacin,multi-minerals,mechanism,DRUG Lomefloxacin reacts faster sucralfate gelusil acidic media whereas erythromycin basic media GROUP neutral media.
745,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,Lomefloxacin,sucralfate,mechanism,Moxifloxacin DRUG reacts faster DRUG gelusil acidic media whereas erythromycin basic media multi minerals neutral media.
746,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,Lomefloxacin,gelusil,mechanism,Moxifloxacin DRUG reacts faster sucralfate BRAND acidic media whereas erythromycin basic media multi minerals neutral media.
747,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,Lomefloxacin,erythromycin,mechanism,Moxifloxacin DRUG reacts faster sucralfate gelusil acidic media whereas DRUG basic media multi minerals neutral media.
748,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,Lomefloxacin,multi-minerals,mechanism,Moxifloxacin DRUG reacts faster sucralfate gelusil acidic media whereas erythromycin basic media GROUP neutral media.
749,Methysergide may reverse the analgesic activity of narcotic analgesics. ,Methysergide,narcotic analgesics,effect,DRUG may reverse analgesic activity GROUP .
750,Zidovudine competitively inhibits the intracellular phosphorylation of stavudine. ,Zidovudine,stavudine,effect,DRUG competitively inhibits intracellular phosphorylation DRUG .
751,"Therefore, use of zidovudine in combination with ZERIT should be avoided. ",zidovudine,ZERIT,advise,Therefore use DRUG combination BRAND avoided.
752,In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by doxorubicin and ribavirin. ,stavudine,doxorubicin,effect,vitro data indicate phosphorylation DRUG also inhibited relevant concentrations DRUG ribavirin.
753,In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by doxorubicin and ribavirin. ,stavudine,ribavirin,effect,vitro data indicate phosphorylation DRUG also inhibited relevant concentrations doxorubicin DRUG .
754,"When administered concurrently, testolactone may increase the effects of oral anticoagulants; ",testolactone,anticoagulants,effect,administered concurrently DRUG may increase effects oral GROUP ;
755,Paroxetine and fluoxetine reduce the plasma concentration of endoxifen by about 50%. ,Paroxetine,endoxifen,mechanism,DRUG fluoxetine reduce plasma concentration DRUG_N 50%.
756,Paroxetine and fluoxetine reduce the plasma concentration of endoxifen by about 50%. ,fluoxetine,endoxifen,mechanism,Paroxetine DRUG reduce plasma concentration DRUG_N 50%.
757,"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. ",tamoxifen,SSRI antidepressants,advise,better avoid prescribing isoenzyme CYP 2D6 inhibitors women treated DRUG breast cancer especially GROUP paroxetine fluoxetine.
758,"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. ",tamoxifen,paroxetine,advise,better avoid prescribing isoenzyme CYP 2D6 inhibitors women treated DRUG breast cancer especially SSRI antidepressants DRUG fluoxetine.
759,"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. ",tamoxifen,fluoxetine,advise,better avoid prescribing isoenzyme CYP 2D6 inhibitors women treated DRUG breast cancer especially SSRI antidepressants paroxetine DRUG .
760,"If in certain cases, an antidepressant is considered necessary, it may be advisable to replace tamoxifen with anastrozole.",antidepressant,tamoxifen,advise,certain cases GROUP considered necessary may advisable replace DRUG anastrozole.
761,"But the use of fixed combination amlodipine/valsartan compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of antihypertensive drugs (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05). ",amlodipine,valsartan,effect,use fixed combination DRUG / DRUG compared traditional therapy associated lower clinical self measured BP quicker achievement target BP (5.8+/ 2.3 9.2+/ 1.8 days respectively 0.05) lesser number antihypertensive drugs (2.5+/ 0.6 3.0+/ 0.9 days respectively) lower rate concealed inefficacy treatment (12 31% respectively 0.05).
762,"We have demonstrated appropriateness of inhospital administration of fixed amlodipine/valsartan combination as an approach allowing to achieve target BP in shorter time, with the use of fewer antihypertensive drugs, and diminishing concealed inefficacy of treatment.",amlodipine,valsartan,effect,demonstrated appropriateness inhospital administration fixed DRUG / DRUG combination approach allowing achieve target BP shorter time use fewer antihypertensive drugs diminishing concealed inefficacy treatment.
763,Cholestyramine: Concomitant cholestyramine administration decreased the mean AUC of total ezetimibe approximately 55%. ,cholestyramine,ezetimibe,mechanism,Cholestyramine: Concomitant DRUG administration decreased mean AUC total DRUG approximately 55%.
764,The incremental LDL-C reduction due to adding ezetimibe to cholestyramine may be reduced by this interaction. ,ezetimibe,cholestyramine,effect,incremental LDL C reduction due adding DRUG DRUG may reduced interaction.
765,Co-administration of ZETIA with fibrates is not recommended until use in patients is studied. ,ZETIA,fibrates,advise,Co administration BRAND GROUP recommended use patients studied.
766,"Fenofibrate: In a pharmacokinetic study, concomitant fenofibrate administration increased total ezetimibe concentrations approximately 1.5-fold. ",fenofibrate,ezetimibe,mechanism,Fenofibrate: pharmacokinetic study concomitant DRUG administration increased total DRUG concentrations approximately 1.5 fold.
767,"Cyclosporine: The total ezetimibe level increased 12-fold in one renal transplant patient receiving multiple medications, including cyclosporine. ",ezetimibe,cyclosporine,mechanism,Cyclosporine: total DRUG level increased 12 fold one renal transplant patient receiving multiple medications including DRUG .
768,Patients who take both ezetimibe and cyclosporine should be carefully monitored. ,ezetimibe,cyclosporine,advise,Patients take DRUG DRUG carefully monitored.
769,Imexon and dacarbazine show additive effects in vitro but not in vivo in human A375 melanoma cells.,Imexon,dacarbazine,effect,DRUG DRUG show additive effects vitro vivo human A375 melanoma cells.
770,"Acute administration of hemantane or doxycycline failed to influence locomotion in mice, while their combination normalized motor activity. ",hemantane,doxycycline,effect,Acute administration DRUG_N DRUG failed influence locomotion mice combination normalized motor activity.
771,"However, ketoconazole, a potent inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing.",ketoconazole,mometasone furoate,mechanism,However DRUG potent inhibitor cytochrome P450 3A4 may increase plasma levels DRUG concomitant dosing.
772,"ABT decreased the toxicity of precocene I, increased exposure to parent compound, and decreased metabolite levels in a dose-dependent manner. ",ABT,precocene I,effect,DRUG_N decreased toxicity DRUG_N increased exposure parent compound decreased metabolite levels dose dependent manner.
773,"Furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene I toxicity. ",quinidine,precocene I,effect,Furafylline sulfaphenazole effect DRUG appeared augment DRUG_N toxicity.
774,"SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.",SKELAXIN,alcohol,effect,BRAND may enhance effects DRUG barbiturates CNS depressants.
775,"SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.",SKELAXIN,barbiturates,effect,BRAND may enhance effects alcohol GROUP CNS depressants.
776,"SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.",SKELAXIN,CNS depressants,effect,BRAND may enhance effects alcohol barbiturates GROUP .
